载去甲万古霉素钢板的研制及防治兔胫骨感染的实验研究
|
摘要
研究背景及研究目的
随着材料科学和临床医学的发展,骨科手术率和术中各种内、外固定器械的使用率日益上升。但是相伴而生的骨和软组织感染作为骨科手术最常见和复杂的并发症,也早已成为骨科医生所面临的极富挑战性的难题之一。据AO组织2006年报道:每年在美国约有200万例院内感染病例,其中约50%与内植物有关。在使用内固定的人群中约5%发生了感染。同时,内固定术后感染可能还会导致包括由于全身应用抗生素、多次清创翻修手术、住院时间延长、截肢甚至死亡等对患者不利的严重后果。因此,内固定术后感染早已成为研究焦点之一。
目前观点认为,与内固定术后感染主要表现为软组织感染和骨髓炎两种形式,是使用内固定所导致的严重并发症之一。尤其在开放性骨折中,各种固定器材包括钢板螺丝钉、外固定支架、髓内针等均可能和感染有关。资料显示:通常闭合性骨折的感染率约1.5%,而开放性骨折的感染率则高达3-40%。创伤所致的开放性骨折呈逐年上升的趋势。在开放性骨折中约60%以上的在损伤时受到了细菌的污染(5,10,11)。术后为预防感染,医生都会大剂量使用广谱抗生素。但是,尽管采取了上述积极的措施,不幸的是仍有一部分患者发生了感染(3)。对这部分病人的后期处理是骨科领域非常棘手的一个问题。
骨折后通常会使用内固定或者外固定材料来固定骨折部位。而内固定具有固定效果确定,便于早期进行功能锻炼,便于护理的优点,在患者病情允许情况下,是骨科医生的首选。钢板往往被推荐在闭合性骨折和GustiloI型开放性骨折中使用。一般认为,伤口是否发生感染主要取决于伤口的性质、细菌的数量与毒力和宿主抵抗能力,以及伤口内异物的存留。最常见的导致“固定物与感染”的细菌为金黄色葡萄球菌和表皮葡萄球菌。金黄色葡萄球菌和表皮葡萄球菌均可以产生生物膜。生物膜的形成分两部进行(39),首先是细菌黏附于固定物的表面,然后细菌之间相互黏附形成多层状的细菌以进入细菌静止或休眠期,从而抵抗临床抗生素治疗和免疫系统的吞噬细胞清除细菌。金黄色葡萄球菌是导致手术或创伤后的主要致病菌(30%),是内植物相关的骨与关节、软组织感染的首要细菌。它一旦进入淋巴管或血液中,将导致脓毒症。耐甲氧西林金黄色葡萄球菌(methicillin-resistant S.aureus MRSAs)具有耐β-内酰胺类抗生素如青霉素、三代头孢、链霉素、四环素及磺胺类药物的特点,并且对氨基糖肽类抗生素和万古霉素的敏感性也在降低。目前已有对万古霉素和替考拉宁耐药的报道。当金黄色葡萄球菌黏附在固定物表面时,人体细胞并不能将其清除掉。骨感染的结果就是急性或慢性骨髓炎。其病理类型与细菌类型无关,但是金葡菌感染更易于产生慢性侵袭性骨髓炎。
按照感染发生的时间,主要将其分为三类:早期感染(小于2周),主要在创伤或固定手术期间获得感染,是高致病性微生物感染(金葡菌、革兰氏阴性杆菌)所致。延迟感染(2-10周)和晚期感染(超过10周),主要在创伤或固定手术期间获得感染,低致病性微生物感染(凝固酶阴性葡萄球菌),偶尔由远隔部位的血源性播种所致。早期感染的临床症状出现得较早并持续出现局部疼痛、大血肿、发热,常见致病菌为高毒力型,当伤口愈合受到影响的时候,必须积极地寻找伤口的坏死边缘和术后的血肿及感染灶(96,97)。延迟和晚期感染的临床表现、治疗及预后相似。一般表现为持续或者加重的疼痛、假关节形成、固定物松动、有时出现的窦道是延迟感染的标志。但也有临床症状和体征缺乏的病例。其主要致病菌为低毒力型。其可能发生的原因是早期抗感染的力度不足以使微生物彻底根除,与假体关节感染相反,固定物所导致的晚期感染发生频率较低(98)。
内固定术后感染的治疗包括手术治疗和抗生素治疗,抗生素的使用往往在配合手术翻修或取出固定物和彻底清创的基础上使用。针对抗生素的使用方法可以归纳为全身使用和局部使用两类。局部抗生素的使用是治疗固定物感染的重要措施之一,目前多采用缓释载体载抗生素以期在局部产生较长时间的局部高浓度抗生素。其基本理念均为:抗生素在特定的部位逐步地释放抗生素,获得较全身性使用抗生素更高的浓度。
在目前内固定术后感染发生率高、抗生素耐药菌株日益增加和系统性全身应用抗生素局限性逐渐被认识的背景下,局部预防性或治疗性应用抗生素已成为在固定物相关感染的治疗中具有前景的主要措施之一。尤其是把固定物与抗生素组合或者合成在一起的途径,对医生来说极具吸引力。这种设想把固定物本身变成了“抗生素释放系统”,其好处是显而易见的:在同往常一样植入固定物的同时获得了额外的局部释放抗生素的益处,使局部聚集了高浓度的抗生素而很少有全身性的副作用,特别是在如髓内针固定术等闭合性复位的手术中,更有利于患者的治疗。同时,通过生物降解材料可以把抗生素物质限定在一定的时间段内释放以产生合理的药效学,最大程度的减少了对耐药菌株筛选的风险。因此被看作是骨科器械发展的“未来”。
抗生素涂层的理论首先由Darouice于1998年提出并实施。目前应用较多的途径是生物降解材料如聚D,L-乳酸(poly D,L-Lactide PDLLA)负载抗生素以达到预防或治疗感染的目的。局部抗生素释放系统应该达到以下基本要求:缓释技术必须保证快速释放超过MIC浓度水平的抗生素;药物释放必须在一定的时间内,避免产生耐药性菌株;杀菌性抗生素应该产生杀菌效应,而不是仅仅抑菌;药物缓释系统应该自行降解。PDLLA涂层不仅具备上述条件,而且有利于阻止细菌黏附在固定物表面。
MRSA对绝大多数抗生素交叉耐药,但是仍然对万古霉素或去甲万古霉素100%敏感。在体外药敏实验中,去甲万古霉素对MRSA非常有效,而且与其它种类的抗菌药物无交叉耐药。另外用MRSA在试管内进行传代培养试验,其对万古霉素的诱导耐药性也很低。去甲万古霉素能够抑制细菌细胞壁的合成,发挥杀菌作用。另外还可以通过改变细菌细胞壁的通透性,阻碍细菌RNA的合成的机制杀灭细菌。目前,去甲万古霉素对MRSA的MIC90为0.5-3.1mg/L。
因此,在内固定表面涂层技术渐趋成熟的启示下,我们采用治疗金葡菌感染的特效药物去甲万古霉素,研制出“载去甲万古霉素聚乳酸缓释钢板”。自内而外的早期释放去甲万古霉素,直接杀灭金葡菌,破坏或阻碍固定物表面生物膜的形成,通过检测该钢板释放去甲万古霉素的释放动力学及其对金黄色葡萄球菌体外抑菌作用和新西兰大白兔胫骨中段横断模型,探讨其在创伤性骨髓炎的预防和治疗的应用前景。
实验方法
1.采用乙酸乙酯、丙酮、水的三元溶剂组合,运用溶胶-凝胶法制作载去甲万古霉素钢板。
2.将两种钢板分别浸于1ml和10ml的浸提液中,应用凝胶渗透色谱和高效液相色谱仪分别检测PDLLA的降解和去甲万古霉素的局部释放浓度,了解该钢板释放去甲万古霉素的动力学过程。
3.将载万古霉素钢板和普通钢板分别与不同浓度的金葡菌混悬液进行普通培养后计数金葡菌菌落数。扫描电镜检查钢板金葡菌在两种钢板表面的黏附情况。
4.制备胫骨中段单侧皮质横断骨折并金葡菌污染模型,分别置入载去甲万古霉素缓释钢板和普通不锈钢钢板,比较两种钢板对兔胫骨金葡菌感染模型的预防作用。
5.制备兔胫骨中段单侧皮质横断骨折并感染的模型。分别置入载去甲万古霉素缓释钢板和普通不锈钢钢板,比较两种钢板对兔胫骨金葡菌感染模型的治疗作用。
实验结果
1.采用乙酸乙酯、丙酮、水的三元溶剂组合,运用溶胶-凝胶法制作载去甲万古霉素聚乳酸缓释钢板。涂层中的聚D,L-乳酸(poly D,L-Lactide, PDLLA)降解失重率在第1、3、7、14、28天分别为0.4%、0.9%、1.75%、2.65%、4.76%。涂层中去甲万古霉素的局部释放浓度在35天内均高于去甲万古霉素对金葡菌的最低抑菌浓度。
2.载去甲万古霉素缓释钢板可以有效降低兔胫骨金黄色葡萄球菌污染模型的感染率。提示涂层中释放的去甲万古霉素在可以有效杀灭伤口污染的金葡菌。
3.载去甲万古霉素缓释钢板可以有效降低胫骨金黄色葡萄球菌污染模型大白兔术后第3、7、14天静脉血白细胞计数和CRP含量。但是对大白兔的肛温和体重没有影响。
4.载去甲万古霉素钢板周围组织中去甲万古霉素的浓度在植入后28天仍然达到最低抑菌浓度。同时血浆中的浓度极低。可以有效避免全身使用去甲万古霉素的副作用。
5.载去甲万古霉素缓释钢板对胫骨感染性骨折兔的感染控制率高于普通钢板。
结论
1.采用溶胶-凝胶法可以成功制作载去甲万古霉素聚乳酸钢板。在检测的35天内,该钢板在体外释放去甲万古霉素的释放动力学稳定,同时盐酸去甲万古霉素的载体PDLLA也能稳定、匀速地降解。
2.释放的盐酸去甲万古霉素可以有效抑制金葡菌菌落的生长以及减少其金葡菌在钢板表面的黏附,说明载去甲万古霉素缓释钢板在体外可以有效抑菌。为该钢板在体内实验中的应用奠定基础。
3.在预防兔胫骨感染的体内实验中,载去甲万古霉素缓释钢板组较普通钢板组为低,两组间感染率有明显区别;从白细胞计数、CRP含量、组织学和放射学角度观察,载去甲万古霉素缓释钢板不仅在体外可以有效抑菌,而且能够预防兔胫骨金黄色葡萄球菌污染模型发生感染。为该钢板过渡到临床应用提供了实验依据。
4.载去甲万古霉素钢板治疗对内固定术后感染可能有一定的疗效。
With the development of materials and medicine, it has increased greatly in the rate of operation and the rate of uesing the fixation device. But at the same time, the infection following with operations and fixation devices became a big tough problem. It was reported by AO that 50% of 2 millions infection cases in one year were cause by implants. The severity consequence are large dose antibiotics applicated all over the body, many times overhauling operations, prolongation of staying in hospital, amputation and death and so on. So, the infection following with the fixation devices has become a focus .
Soft tissue infection and carious osteitis are the two kinds of appearances which are accompany by the fixation devices. Especially in open fracture, all kinds of fixation devices , e.g. steel plate, screw, external fixatior and intramedullary nail et al, can accompany bone infection. Some date were reported that the infection rate was 1.5% in closed fracture. But in compound fracture, the infection rate increased to 3-40%. With the development of transportation, the proportation of compound fracture has been increasing gradually. Above 60% of those fracture were polluted by bacteriums. So, for preventing infection, large dose of broad-spectrum was used. A lot of active steps were adopted, but a part of patiences were infected. How to treat those patiences? The orthopedists have no good ideas.
After fracture, internal or external fixations are used. The internal fixation is the first choice in suitable cases. The steel plate is prefered in closed fracture and Gustilo I compound fracture. Many matters can caused infection. For example, the wound, the quantity and toxcity of bacteriums and the extraneous matter in wound. The straphylococcus aureus (SA) and straphylococcus epidermidis (SE) are detected usually in infected wound implanted in fixation device. All of SA and SE can produce biological membrane. Firstly, the bacteriums acctete the surface of fixation device. Secondly, those bacteriums can possess each other to form multilayer bacterium lamellar for resist the antibiotics and phagocyte. The SA is the main pathogenic bacteria after operation or trauma. At same time it is chief bacteria related with infection in bone, joint and soft tissue also. Methicillin-resistant S.aureus (MRSAs) are kind of SA which are drug fast to peniciline, tert-cephalosporin, phytomycin, ambramycin.
The phagocyte can not kill the SA adhering at surface of fixation device. The infection caused by SA can induce facilely to chronic invasive carious osteitis.
According to the time of infection, the infection can be classified to III species. The early period infection which genesis in 2 weeks is caused by trauma or operation. The pathogenic bacteria is hypsi-invasive organism, e.g. SA, gram-negative bacillus. The delay infection which genesis in 2nd to 10th week and the advanced stage infection which genesis exceed 10 weeks are caused by trauma and operation also. The pathogenic bacteria is hypo-invasive organism, e.g. coagulase negative staphylococcus (CN-S). The clinical symptom of early infection is pain, blood tumor, fever and so on. The delay and advanced stage infection have same clinical symptom. The patients are contiue and aggravated pain, pseudoarticulation formation, fixation device cinch. Some there is sinuses which is the mark of delay infection. Be different with infection of prosthesis joint, the infection connected with fixation device is early infection mainly.
To treat the infection connected with fixation device, an operation must to be done is to take out of the device. At same time, a large dose antibiotics is used. This is an important measure that antibiotics is used at regions. Now, the delayed release antibiotics connected with delayed release supporter are uesd for longer hypso-density in regions.
The antibiotics coating was raised and practiced firstly by Darouice.
Now, the poly D,L-Lactide (PDLLA) is used generally. The relayed release qntibiotics coating must be to achieve requirements: 1) The antibiotics in coating must be released that density of regional antibiotics exceeds the minimal inhibitory concentration (MIC);2) The release must keep on a long time to aviod drug resistance strain; 3) The bactericidal antibiotic must be bactericidal effect, but bacteriostasis; 4) The supporter must degradate initiativly. The PDLLA not only achieve all requirements, but also can prevent bacterial adhesion.
Though MRSA is drug fast to many antibiotics, it is sensitive to vancomycin and norvancomycin. In vitro, norvancomycin is effective extremely to MRSA. And there is achiasmate drug fast with others. Norvancomycin can inhibit composition of cell wall and RNA. The MIC90 OF norvancomycin to MRSA is 0.5-3.1mg/L.
In this study, we advanced developed the steel plate coating with delayed release PDLLA- norvancomycin and research the function of preventing infection in open fracture.
There are some results.
1.Acetoacetate, acetone and water were used to manufacture coating by collosol-gel method. The degradation agravity rate of PDLLA is 0.4%,0.9%,1.75%,2.65%,4.76% at 1st,3rd,7th,14th and 28th day. In 35 days, the released norvancomycin are higher than MIC90 to SA.
2. The infection rate in expermental group was lower than that in contral. It is suggested that the released norvancomycin from steel plate’s coating can kill the SA in tibia. But the steel plate coating with delayed release PDLLA- norvancomycin can not treat the infection in open fracture.
3. The WBC and CRP were lower in experimental group at 3rd, 7th, 14th day after operation than that in contral. But there were difference in rectal temperature and weight among two groups.
4. In 28th day after steel plate implanted into rabbits, the norvancomycin concentration of surrounding tissue was not lower than MIC90. At same time, the norvancomycin concentration of blood plasm was very low. So, the side effect of norvancomycin could be avoided.
5. The steel plate coating with delayed release PDLLA- norvancomycin controlled 13 of 25 rabbits treated the infection in open fracture.While the stainless steel only controlled 5 of 25 rabbits treated the infection in open fracture.The controlled rate were 52% vs 20%. But there was not statistically significant between the two groups.
随着材料科学和临床医学的发展,骨科手术率和术中各种内、外固定器械的使用率日益上升。但是相伴而生的骨和软组织感染作为骨科手术最常见和复杂的并发症,也早已成为骨科医生所面临的极富挑战性的难题之一。据AO组织2006年报道:每年在美国约有200万例院内感染病例,其中约50%与内植物有关。在使用内固定的人群中约5%发生了感染。同时,内固定术后感染可能还会导致包括由于全身应用抗生素、多次清创翻修手术、住院时间延长、截肢甚至死亡等对患者不利的严重后果。因此,内固定术后感染早已成为研究焦点之一。
目前观点认为,与内固定术后感染主要表现为软组织感染和骨髓炎两种形式,是使用内固定所导致的严重并发症之一。尤其在开放性骨折中,各种固定器材包括钢板螺丝钉、外固定支架、髓内针等均可能和感染有关。资料显示:通常闭合性骨折的感染率约1.5%,而开放性骨折的感染率则高达3-40%。创伤所致的开放性骨折呈逐年上升的趋势。在开放性骨折中约60%以上的在损伤时受到了细菌的污染(5,10,11)。术后为预防感染,医生都会大剂量使用广谱抗生素。但是,尽管采取了上述积极的措施,不幸的是仍有一部分患者发生了感染(3)。对这部分病人的后期处理是骨科领域非常棘手的一个问题。
骨折后通常会使用内固定或者外固定材料来固定骨折部位。而内固定具有固定效果确定,便于早期进行功能锻炼,便于护理的优点,在患者病情允许情况下,是骨科医生的首选。钢板往往被推荐在闭合性骨折和GustiloI型开放性骨折中使用。一般认为,伤口是否发生感染主要取决于伤口的性质、细菌的数量与毒力和宿主抵抗能力,以及伤口内异物的存留。最常见的导致“固定物与感染”的细菌为金黄色葡萄球菌和表皮葡萄球菌。金黄色葡萄球菌和表皮葡萄球菌均可以产生生物膜。生物膜的形成分两部进行(39),首先是细菌黏附于固定物的表面,然后细菌之间相互黏附形成多层状的细菌以进入细菌静止或休眠期,从而抵抗临床抗生素治疗和免疫系统的吞噬细胞清除细菌。金黄色葡萄球菌是导致手术或创伤后的主要致病菌(30%),是内植物相关的骨与关节、软组织感染的首要细菌。它一旦进入淋巴管或血液中,将导致脓毒症。耐甲氧西林金黄色葡萄球菌(methicillin-resistant S.aureus MRSAs)具有耐β-内酰胺类抗生素如青霉素、三代头孢、链霉素、四环素及磺胺类药物的特点,并且对氨基糖肽类抗生素和万古霉素的敏感性也在降低。目前已有对万古霉素和替考拉宁耐药的报道。当金黄色葡萄球菌黏附在固定物表面时,人体细胞并不能将其清除掉。骨感染的结果就是急性或慢性骨髓炎。其病理类型与细菌类型无关,但是金葡菌感染更易于产生慢性侵袭性骨髓炎。
按照感染发生的时间,主要将其分为三类:早期感染(小于2周),主要在创伤或固定手术期间获得感染,是高致病性微生物感染(金葡菌、革兰氏阴性杆菌)所致。延迟感染(2-10周)和晚期感染(超过10周),主要在创伤或固定手术期间获得感染,低致病性微生物感染(凝固酶阴性葡萄球菌),偶尔由远隔部位的血源性播种所致。早期感染的临床症状出现得较早并持续出现局部疼痛、大血肿、发热,常见致病菌为高毒力型,当伤口愈合受到影响的时候,必须积极地寻找伤口的坏死边缘和术后的血肿及感染灶(96,97)。延迟和晚期感染的临床表现、治疗及预后相似。一般表现为持续或者加重的疼痛、假关节形成、固定物松动、有时出现的窦道是延迟感染的标志。但也有临床症状和体征缺乏的病例。其主要致病菌为低毒力型。其可能发生的原因是早期抗感染的力度不足以使微生物彻底根除,与假体关节感染相反,固定物所导致的晚期感染发生频率较低(98)。
内固定术后感染的治疗包括手术治疗和抗生素治疗,抗生素的使用往往在配合手术翻修或取出固定物和彻底清创的基础上使用。针对抗生素的使用方法可以归纳为全身使用和局部使用两类。局部抗生素的使用是治疗固定物感染的重要措施之一,目前多采用缓释载体载抗生素以期在局部产生较长时间的局部高浓度抗生素。其基本理念均为:抗生素在特定的部位逐步地释放抗生素,获得较全身性使用抗生素更高的浓度。
在目前内固定术后感染发生率高、抗生素耐药菌株日益增加和系统性全身应用抗生素局限性逐渐被认识的背景下,局部预防性或治疗性应用抗生素已成为在固定物相关感染的治疗中具有前景的主要措施之一。尤其是把固定物与抗生素组合或者合成在一起的途径,对医生来说极具吸引力。这种设想把固定物本身变成了“抗生素释放系统”,其好处是显而易见的:在同往常一样植入固定物的同时获得了额外的局部释放抗生素的益处,使局部聚集了高浓度的抗生素而很少有全身性的副作用,特别是在如髓内针固定术等闭合性复位的手术中,更有利于患者的治疗。同时,通过生物降解材料可以把抗生素物质限定在一定的时间段内释放以产生合理的药效学,最大程度的减少了对耐药菌株筛选的风险。因此被看作是骨科器械发展的“未来”。
抗生素涂层的理论首先由Darouice于1998年提出并实施。目前应用较多的途径是生物降解材料如聚D,L-乳酸(poly D,L-Lactide PDLLA)负载抗生素以达到预防或治疗感染的目的。局部抗生素释放系统应该达到以下基本要求:缓释技术必须保证快速释放超过MIC浓度水平的抗生素;药物释放必须在一定的时间内,避免产生耐药性菌株;杀菌性抗生素应该产生杀菌效应,而不是仅仅抑菌;药物缓释系统应该自行降解。PDLLA涂层不仅具备上述条件,而且有利于阻止细菌黏附在固定物表面。
MRSA对绝大多数抗生素交叉耐药,但是仍然对万古霉素或去甲万古霉素100%敏感。在体外药敏实验中,去甲万古霉素对MRSA非常有效,而且与其它种类的抗菌药物无交叉耐药。另外用MRSA在试管内进行传代培养试验,其对万古霉素的诱导耐药性也很低。去甲万古霉素能够抑制细菌细胞壁的合成,发挥杀菌作用。另外还可以通过改变细菌细胞壁的通透性,阻碍细菌RNA的合成的机制杀灭细菌。目前,去甲万古霉素对MRSA的MIC90为0.5-3.1mg/L。
因此,在内固定表面涂层技术渐趋成熟的启示下,我们采用治疗金葡菌感染的特效药物去甲万古霉素,研制出“载去甲万古霉素聚乳酸缓释钢板”。自内而外的早期释放去甲万古霉素,直接杀灭金葡菌,破坏或阻碍固定物表面生物膜的形成,通过检测该钢板释放去甲万古霉素的释放动力学及其对金黄色葡萄球菌体外抑菌作用和新西兰大白兔胫骨中段横断模型,探讨其在创伤性骨髓炎的预防和治疗的应用前景。
实验方法
1.采用乙酸乙酯、丙酮、水的三元溶剂组合,运用溶胶-凝胶法制作载去甲万古霉素钢板。
2.将两种钢板分别浸于1ml和10ml的浸提液中,应用凝胶渗透色谱和高效液相色谱仪分别检测PDLLA的降解和去甲万古霉素的局部释放浓度,了解该钢板释放去甲万古霉素的动力学过程。
3.将载万古霉素钢板和普通钢板分别与不同浓度的金葡菌混悬液进行普通培养后计数金葡菌菌落数。扫描电镜检查钢板金葡菌在两种钢板表面的黏附情况。
4.制备胫骨中段单侧皮质横断骨折并金葡菌污染模型,分别置入载去甲万古霉素缓释钢板和普通不锈钢钢板,比较两种钢板对兔胫骨金葡菌感染模型的预防作用。
5.制备兔胫骨中段单侧皮质横断骨折并感染的模型。分别置入载去甲万古霉素缓释钢板和普通不锈钢钢板,比较两种钢板对兔胫骨金葡菌感染模型的治疗作用。
实验结果
1.采用乙酸乙酯、丙酮、水的三元溶剂组合,运用溶胶-凝胶法制作载去甲万古霉素聚乳酸缓释钢板。涂层中的聚D,L-乳酸(poly D,L-Lactide, PDLLA)降解失重率在第1、3、7、14、28天分别为0.4%、0.9%、1.75%、2.65%、4.76%。涂层中去甲万古霉素的局部释放浓度在35天内均高于去甲万古霉素对金葡菌的最低抑菌浓度。
2.载去甲万古霉素缓释钢板可以有效降低兔胫骨金黄色葡萄球菌污染模型的感染率。提示涂层中释放的去甲万古霉素在可以有效杀灭伤口污染的金葡菌。
3.载去甲万古霉素缓释钢板可以有效降低胫骨金黄色葡萄球菌污染模型大白兔术后第3、7、14天静脉血白细胞计数和CRP含量。但是对大白兔的肛温和体重没有影响。
4.载去甲万古霉素钢板周围组织中去甲万古霉素的浓度在植入后28天仍然达到最低抑菌浓度。同时血浆中的浓度极低。可以有效避免全身使用去甲万古霉素的副作用。
5.载去甲万古霉素缓释钢板对胫骨感染性骨折兔的感染控制率高于普通钢板。
结论
1.采用溶胶-凝胶法可以成功制作载去甲万古霉素聚乳酸钢板。在检测的35天内,该钢板在体外释放去甲万古霉素的释放动力学稳定,同时盐酸去甲万古霉素的载体PDLLA也能稳定、匀速地降解。
2.释放的盐酸去甲万古霉素可以有效抑制金葡菌菌落的生长以及减少其金葡菌在钢板表面的黏附,说明载去甲万古霉素缓释钢板在体外可以有效抑菌。为该钢板在体内实验中的应用奠定基础。
3.在预防兔胫骨感染的体内实验中,载去甲万古霉素缓释钢板组较普通钢板组为低,两组间感染率有明显区别;从白细胞计数、CRP含量、组织学和放射学角度观察,载去甲万古霉素缓释钢板不仅在体外可以有效抑菌,而且能够预防兔胫骨金黄色葡萄球菌污染模型发生感染。为该钢板过渡到临床应用提供了实验依据。
4.载去甲万古霉素钢板治疗对内固定术后感染可能有一定的疗效。
With the development of materials and medicine, it has increased greatly in the rate of operation and the rate of uesing the fixation device. But at the same time, the infection following with operations and fixation devices became a big tough problem. It was reported by AO that 50% of 2 millions infection cases in one year were cause by implants. The severity consequence are large dose antibiotics applicated all over the body, many times overhauling operations, prolongation of staying in hospital, amputation and death and so on. So, the infection following with the fixation devices has become a focus .
Soft tissue infection and carious osteitis are the two kinds of appearances which are accompany by the fixation devices. Especially in open fracture, all kinds of fixation devices , e.g. steel plate, screw, external fixatior and intramedullary nail et al, can accompany bone infection. Some date were reported that the infection rate was 1.5% in closed fracture. But in compound fracture, the infection rate increased to 3-40%. With the development of transportation, the proportation of compound fracture has been increasing gradually. Above 60% of those fracture were polluted by bacteriums. So, for preventing infection, large dose of broad-spectrum was used. A lot of active steps were adopted, but a part of patiences were infected. How to treat those patiences? The orthopedists have no good ideas.
After fracture, internal or external fixations are used. The internal fixation is the first choice in suitable cases. The steel plate is prefered in closed fracture and Gustilo I compound fracture. Many matters can caused infection. For example, the wound, the quantity and toxcity of bacteriums and the extraneous matter in wound. The straphylococcus aureus (SA) and straphylococcus epidermidis (SE) are detected usually in infected wound implanted in fixation device. All of SA and SE can produce biological membrane. Firstly, the bacteriums acctete the surface of fixation device. Secondly, those bacteriums can possess each other to form multilayer bacterium lamellar for resist the antibiotics and phagocyte. The SA is the main pathogenic bacteria after operation or trauma. At same time it is chief bacteria related with infection in bone, joint and soft tissue also. Methicillin-resistant S.aureus (MRSAs) are kind of SA which are drug fast to peniciline, tert-cephalosporin, phytomycin, ambramycin.
The phagocyte can not kill the SA adhering at surface of fixation device. The infection caused by SA can induce facilely to chronic invasive carious osteitis.
According to the time of infection, the infection can be classified to III species. The early period infection which genesis in 2 weeks is caused by trauma or operation. The pathogenic bacteria is hypsi-invasive organism, e.g. SA, gram-negative bacillus. The delay infection which genesis in 2nd to 10th week and the advanced stage infection which genesis exceed 10 weeks are caused by trauma and operation also. The pathogenic bacteria is hypo-invasive organism, e.g. coagulase negative staphylococcus (CN-S). The clinical symptom of early infection is pain, blood tumor, fever and so on. The delay and advanced stage infection have same clinical symptom. The patients are contiue and aggravated pain, pseudoarticulation formation, fixation device cinch. Some there is sinuses which is the mark of delay infection. Be different with infection of prosthesis joint, the infection connected with fixation device is early infection mainly.
To treat the infection connected with fixation device, an operation must to be done is to take out of the device. At same time, a large dose antibiotics is used. This is an important measure that antibiotics is used at regions. Now, the delayed release antibiotics connected with delayed release supporter are uesd for longer hypso-density in regions.
The antibiotics coating was raised and practiced firstly by Darouice.
Now, the poly D,L-Lactide (PDLLA) is used generally. The relayed release qntibiotics coating must be to achieve requirements: 1) The antibiotics in coating must be released that density of regional antibiotics exceeds the minimal inhibitory concentration (MIC);2) The release must keep on a long time to aviod drug resistance strain; 3) The bactericidal antibiotic must be bactericidal effect, but bacteriostasis; 4) The supporter must degradate initiativly. The PDLLA not only achieve all requirements, but also can prevent bacterial adhesion.
Though MRSA is drug fast to many antibiotics, it is sensitive to vancomycin and norvancomycin. In vitro, norvancomycin is effective extremely to MRSA. And there is achiasmate drug fast with others. Norvancomycin can inhibit composition of cell wall and RNA. The MIC90 OF norvancomycin to MRSA is 0.5-3.1mg/L.
In this study, we advanced developed the steel plate coating with delayed release PDLLA- norvancomycin and research the function of preventing infection in open fracture.
There are some results.
1.Acetoacetate, acetone and water were used to manufacture coating by collosol-gel method. The degradation agravity rate of PDLLA is 0.4%,0.9%,1.75%,2.65%,4.76% at 1st,3rd,7th,14th and 28th day. In 35 days, the released norvancomycin are higher than MIC90 to SA.
2. The infection rate in expermental group was lower than that in contral. It is suggested that the released norvancomycin from steel plate’s coating can kill the SA in tibia. But the steel plate coating with delayed release PDLLA- norvancomycin can not treat the infection in open fracture.
3. The WBC and CRP were lower in experimental group at 3rd, 7th, 14th day after operation than that in contral. But there were difference in rectal temperature and weight among two groups.
4. In 28th day after steel plate implanted into rabbits, the norvancomycin concentration of surrounding tissue was not lower than MIC90. At same time, the norvancomycin concentration of blood plasm was very low. So, the side effect of norvancomycin could be avoided.
5. The steel plate coating with delayed release PDLLA- norvancomycin controlled 13 of 25 rabbits treated the infection in open fracture.While the stainless steel only controlled 5 of 25 rabbits treated the infection in open fracture.The controlled rate were 52% vs 20%. But there was not statistically significant between the two groups.
引文
1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422-1429.
2. Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol,1999,7:140-141.
3. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621-643.
4. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949-954.
5. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am;1990,72(2):299-304.
6. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14:305-308.
7. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955-959.
8. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
9. Boxma H.Wound infections in fracture surgery. Thesis. University of Amsterdam. 1995
10. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia, 2001,56(2): 201-206.
11. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453-458.
12. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”. Injury, Int. J. Care Injured,2006,37(2):S37-S38.
13. Bach AW, Hansen ST. Plates versus external fixation in severe open tibial shaft fractures. A randomized trial. Clin Orthop Relat Res,1989,241(4):89-94.
14. Worlock P, Slack R, Harvey L, Mawhinney R. The prevention of infection in open fractures: an experimental study of the effect of fracture stability. Injury, 1994,25(1):31-38.
15. Checketts R, Otterburn M, MacEachern G. Pin track infection: definition, incidence and prevention. Int J Orthop Trauma,1993,3(3): 6-18.
16. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299-304.
17. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153-162.
18. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647-649.
19. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325-328.
20. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63-76.
21. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11):677-685.
22. Wilkinson BJ Biology. Crossley KB, Archer GL (eds),The Staphylococci in Human Diseases. New York: Churchill Livingston,1997,1-38
23. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427-5433.
24. Howard BJ, Kloos WE Staphylococci. Howard BJ, Klass II J, Rubin SJ, et al (eds) Clinical and Pathogenic Microbiology. St Louis, Mo: The CV Mosby Co,1987,231-244.
25. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85-90.
26. Waldvogel FA.Staphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489-1510.
27. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am;1985,67(8):1236-1244.
28. Central Public Health Laboratory Surveillance of surgical site infection-in English hospitals 1997-1999. UK.2000.
29. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320-1325.
30. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis,2001,1(3):147-155.
31. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135-136.
32. Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material; J Infect Dis,1988,158(4):693-701.
33. Spangehl MJ, Masri BA, O’Connell JX, et al. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am,1999,81(5):672-683.
34. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33(Suppl 2):94-106.
35. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol, 1999,37(10):3281-3290.
36. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2): 628-631.
37. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414(9):69?88.
38. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
39. Ajioka M, Suizu H , Higuchi C , et al .Aliphatic polyesters and their copolymers synthesized through direct condensation polymerization. Polymer Degradation and Stability,1998,59(2) :137-143.
40. Schindler A, Harper D. Polylactide:Ⅱ.Viscosity-molecular weight relationships and unperturbed chain dimensions.Journal of Polymer Science:Polymer Chemistryition.1979,17∶2593-2599
41. Majola A ,Vainionapaa S ,Vihtonen K,et al . Absorption , bicompatibility and fixation properties of polylactic acid in bone tissue : an experimental study in rats. Clinical Orthopaedics and Related Research, 1991,268(6):260-269.
42. Rozema FR ,Bos R RM,Pennings AJ ,et al.Poly(l-lactide) implants in repair of defects of the orbital floor :an animal study. Journal of Oral and Maxillofacial Surgery,1990,48(12):1305-1309.
43. Bos RRM,Rozema FR,Boering G,et al.Degradation of and tissue reaction to biodegradable poly (l-lactide) for use as internal fixation of fractures:A study in rats.Biomaterials,1991,12(1) :32-36.
44. Tormala P ,Vaiionpaa S , Kilpikari J ,et al.The effects of fiber reinforcement and gold plating on the flexual and tensile strength of PGA/PLA copolymer materials in vitro.Biomaterials,1987,8(1) 42-45.
45. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
46. Lucke M, Schmidmaier G, Sadoni S et al. Gentamicin coating of metal implants reduces implant-related osteomyelitis in rats. Bone,2003,32(5):521?531.
47. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2),S105—S112.
48. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
1. Kulkarni RK,Pani KC,Neuman C,et al.Polylactic acid for Surgery Implants.Arches Surge,1966,93(5):839-843.
2.胡培战,吴兰亭,杨士林.医用生物降解材料-聚乳酸及其共聚物.生物医学工程杂志,1993,10(2):183-193.
3.唐家驹,潘长江,洪玮,等.大黄素/聚乳酸物复合薄膜的制备及抗凝血研究.2006,8(37):1312-1314.
4. Schmidmaier G, Wildemann B, Bail H,et al.Local Application of Growth Factors (Insulin-Like Growth Factor-1 and Transforming Growth Factor-b1) From a Biodegradable Poly(D,L-lactide) Coating of Osteosynthetic Implants Accelerates Fracture Healing in Rats.Bone, 2001,28(4):341–350.
5. Lucke M, Wildemann B,Sadoni S,et al.Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model.Bone,2005, 36(5):770-778.
6.胡洪国,田丰月,闫玉华,等.聚乳酸及其共聚物的国内外研究现状和进展.国外建材科技,2000,21(1):1-4.
7. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85-90.
8. Waldvogel FAStaphylococcus aureus (including toxic shock syndrome). Mandell GL,Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York: Churchill Livingston,1990, 1489-1510.
9. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325-328.
10. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236-1244.
11. Sievert DM, Boulton ML, Stoltman G,et al. Staphylococcus aureus resistant to Vancomycin-United States.2002.MMWR, 2002,51(26):565-569.
12. Bo Shopsin, Barry NK. Molecular epidemiology of methicillin resistant Staphylococcus aureus. Emerg Infect Dis,2001,7(2):323-326.
13.徐小平,高霞,池晓霞,等.葡萄球菌属和肠球菌属耐药性监测研究.中华医院感染学杂志,2006,16(3):324-326.
14.汪复,朱德妹.上海地区细菌耐药性监测[J].中国抗感染化疗杂志, 2002, 2(1):129-131.
15.申正义,孙自镛,王洪波.湖北地区临床细菌耐药性监测.中华医院感染学杂志,2002,12(2):91-94.
16.马越,陈鸿波,李景云,等. 1999～2000年北京和湖北地区金葡菌耐药性分析.中国临床药理学杂志,2002,18(3):185-187.
17. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320?1325.
18. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135?136.
19. Von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11): 677?685.
20. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med,2005,202(2):209?215.
21. Nada T ,Ichiyama S, Osada Y, et al. Comparison of DNA fingerprinting by PFGE and PCR-RFLP of the coagulase gene to distinguish MRSA isolates. J HospInfect,1996,32(4):305-310.
22. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Stap hylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 2000,44(6):1549-1561.
23. Matsuhashi M , Song MD, Ishino F, et al. Molecular cloning of the gene of a penicillin binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol, 1986,167(3):975-986.
24. Hurlimann-Dalei RL, Ryffel C, Kayser FH, et al. Survey of the methicillin resistance-associated genes mecA, mecR 1-mecI,and femA-femB in clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother,1992, 36(12): 2617-2625.
25. Suzuki E, Hiramatsu K, Yokot T. Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for mecA gene distribution. Antimicrob Agents Chem other,1992,36(2):429-435.
26. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-1198.
27. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
28. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury,2006,37(2), S95—S104.
29. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand, 2003,74(6):644-651.
30. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br, 2005,87(2):272-276.
31. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
32. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
33. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
34. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review.Injury, 2006,37(2),S105—S112.
35. Lucke M, Schmidmaier G, Wildemann B,et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
36. Kalicke T, Schierholz J, Schlegel U, et al. Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and in vivo study. J Orthop Res, 2006,24(8): 1622-1640.
37. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
38. Pitt CG, Gratzl MM, Kimmel GL,et al. Aliphatic polyesters II. The degradation of poly(D,Llactide), poly(epsilon-caprolactone) and their copolymers in vivo.Biomaterials, 1981,2(4), 215–220.
39. Cutright DE, Perez B, Beasley JD,et al.Degradation rates of polymers and copolymers of polylactic and polyglycolic acids.Oral Surgery,Oral Medicine,Oral Pathology,1974, 37(1), 142–152.
40. Kohn J,Langer R. Bioresorbable and bioerodible materials. In Biomaterials Science (Ratner BD, Hoffman AS,Schoen FJ), 1996,64–73.
41. Richards RG, Harris LG,Schneider E,et al.Antiseptics and antibiotics on implants. Injury,2006,37(2):S113—S116.
1. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
2. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
3. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453?458.
4. Elek SD, Conen PE. The virulence of staphylococcus pyogenes for man. A study of the problems of wound infection. Br J Exp Pathol,1957,38(6):573?586.
5. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236?1244.
6. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother,1989,33(5):597?601.
7. Gristina A. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res,1994,298(1):106?118.
8. Merritt K, Dowd J. Role of internal fixation in infection of open fractures: Studies with Staphylococcus aureus and Proteus mirabilis. J Orthop Res,1987, 5(1):23?28.
9. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
10. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
11. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14(3):305?308.
12. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955?959.
13. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization ofStaphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325?328.
14. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63?76.
15. Elek S.Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85?90.
16. Waldvogel FA.Staphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489?1510.
17. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427?5433.
18. Spangehl MJ, Masri BA, O’Connell JX, et al.Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am,1999,81(5):672?683.
19. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
20. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153?162.
21. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647?649.
22. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33Suppl 2:94?106.
23. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol,1999,37(10): 3281?3290.
24. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2):628?631.
25. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414:69?88.
26. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.Radiology,2003,226(2):391-398.
27. Ochsner1 PE, Hailemariam S. Histology of osteosynthesis associated bone infection. Injury, Int Care Injured,2006,37(2),S49—S58.
28. Burri C (1979) Posttraumatic osteitis. 2nd ed. Bern, Stuttgart, Wien: Huber-Verlag.
29. Rittmann WW, Perren SM (1974) Cortical bone healing after osteosynthesis and infection. Berlin, Heidelberg, New York: Springer-Verlag.
30. Sevitt S (1981) Bone repair and fracture healing in man. Edinburgh: Churchill Livingstone.
31. B?hm E, H?rster HG [Histological progress studies of osteomyelitis ltreated locally with gentamycin]. Aktuelle Probl Chir Orthop,1979,12:182?186.
32. Ochsner PE, Brunazzi MG. Intramedullary reaming and soft tissue procedures in treatment of chronic osteomyelitis of long bones. Orthopedics,1994,17(5):433?440.
33. Ochsner PE, Sokhegyi A, Petralli C. [The value of computerized tomography in the assessment of chronic osteomyelitis.A radiological, histological and clinical correlation study]. ZOrthop Ihre Grenzgeb,1990,128(3):313?318.
34. Ochsner PE, Baumgart F, Kohler G. Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal Injury,1998, 29 (Suppl)2: B1?B10.
35. Baumgart F, Kohler G, Ochsner PE. The physics of heat generation during reaming of the medullary cavity. Injury,1998,29(Suppl 2): B11?B25.
36. B?hm E. [Chronic posttraumatic osteomyelitis. Morphology and pathogenesis]. Unfallheilkunde,1986,176.
1. Clifford RP (2000) Open fractures. Rüedi TP, Murphy WM(eds), AO Principles of Fracture Management. AO Publishing,Stuttgart New York: Thieme-Verlag: 621-643.
2. Bagnoa A, Genovesea M, Luchinia A,et al.Contact prolometry and correspondence analysis to correlate surface properties and cell adhesion in vitro of uncoated and coated Ti and Ti6Al4V disks. Biomaterials,2004,25:2437–2445.
3. Gollwitzer H, Ibrahim K, Meyer H, et al.Antibacterial poly(D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother,2004,51(3):585-591.
4. Kalicke T, Schierholz J, Schlegel U, et al. Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: An in vitro and in vivo study. J Orthop Res , 2006,24:1622-1640.
5. Schmidmaier1 G, Lucke M, Wildemann1 B,et al.Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37,S105—S112.
6. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59—S66.
7. Darouiche RO. Treatment of infections associated with surgical implants. N Engl JMed,2004,350(14):1422?1429.
8. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249?256.
9. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA,1998, 279(19):1537?1541.
10. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res,1999,(360):22?29.
11. Schlegel U, Perren SM. Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection. Injury,2006,37(2),S67—S73.
12. Melcher G, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. J Bone Joint Surg Br,1994,76(6):955?959.
13. Arens S, Eijer H, Schlegel U, et al. Influence of the design for fixation implants on local infection: Experimental study of dynamic compression plates versus point contact fixators in rabbits. J Orthop Trauma,1999, 13(7):470?476.
14. Horn J, Schlegel U, Krettek C, et al. Infection resistance of unreamed solid, hollow slotted and cannulated intramedullary nails: an in-vivo experimental comparison. J Orthop Res,2005,23(4):810?815.
15. Hauke C, Schlegel U, Melcher GA, et al. Local infection in relation to different implant materials. An experimental study using stainless steel and titanium solid, unlocked, intramedullary nails in rabbits. Orthop Trans,1997,21:835?836.
16. Melcher GA, Metzdorf A, Schlegel U, et al. Influence of reaming versus nonreaming in intramedullary nailing on local infection rate: Experimental investigation in rabbits. J Trauma,1995,39(6):1123?1128.
17. Metzdorf A (1996) Einfluss der Markraumbohrung auf die Entstehung eines lokalen Infektes. Universit?t Würzburg. Dissertation.
18. Arens S, Schlegel U, Printzen G, et al. Influence of materials for fixation implants on local infection. An experimental study of steel versus titanium DCP in rabbits. J BoneJoint Surg Br,1996,78(4):647?651.
19. Eijer H, Arens S, Schlegel U, et al. Einfluss des Implantat-Designs auf die lokale Infektentstehung. Tierexperimentelle Untersuchung von DC-Platten und Point-Contact Fixateuren. Springer Verlag, Berlin. Hefte zu: Der Unfallchirurg,1997,268, 855?856.
20. Magnan B, Regis D, Biscaglia R, et al. Preformed acrylic bone cement spacer loaded with antibiotics: use of two-stage procedure in 10 patients because of infected hips after total replacement.Acta Orthop Scand, 2001, 72(6): 591-594.
21. Langlais F. Antibiotic-loaded bone cements: from laboratory studies clinical evaluation. Bull A cad Natl Med, 2004,188(6):1011-1022.
22. Taggart T, Kerry RM , Norman P, et al.The use of vancomycin-impregnated cement beads in the management of infection of prosthetic joints. J Bone Joint Surg (Br),2002,84(1): 70-72.
23.杨静,段宏,裴福兴.髋关节置换后慢性感染伴窦道形成的手术治疗.中华骨科杂志,2001,21(12): 741-744.
24.王爱民,王子明,唐桂阳,等.万古霉素骨水泥在感染人工髋关节翻修中作用的实验研究与临床观察。中华创伤骨科杂志,2004,6(6):603-607.
25.王子明,王爱民,唐桂阳.兔人工股骨头置换后感染模型的建立及万古霉素-聚甲基丙烯酸甲酯的预防作用.中华创伤杂志,2002,18(11):667-670.
26. Cabanela ME.Open cancellous bone grafting of infected bone defects.Orthop Clin North Am,1984,15(3):427-440.
27. Patzakis MJ,Scilaris TA,Chon J,et al.Result of bone grafting for infected tibial nonunion. Clin Orthop,1995,315(6):192-198.
28. Emami A,Mjoberg B,Larsson S.Infected tibial nonunion.Good result after open cancellous bone grafting in 37 cases.Acta Orthop Scand,1995,66(5):447-451.
29. Esterhal JL,Sennett B,Gelb H,et al.Treatment of chronic osteomylitis complicating nonunion and segemental defects of the tibial with open cancellous bone graft, posterolateral bone graft,and soft–tissue tranfer.J trauma,1990,30(7):49-54.
30. Green SA,Dlabal TA.The open bone graft for septic nonunion. Clin Orthop,1983,180(11):117-124.
31. Papineau LJ,Alfageme A.Chronic osteomylitis of long bone resection and bone grafting with delayed skin closure.J Bone J Surg(Br), 1976,58:138.
32.刘德全,张伯松,刘洪波,等.一期开放松质骨植骨治疗感染性骨缺损的实验研究.中华创伤骨科杂志,2004,6(12):1370-1373.
33. Patzakis MJ, Wilkins J, Wiss DA. Infected following intramedullary nailing of long bones: diagnosis and manegement. Clin Orthop,1986,212(11):182-191.
34. Ueng WN,Shih CH.Manegement of infected tibial intramedullary nailing using an organized treatment protocal.J Formos Med Assoc,1992,91(9):879-885.
35.郑强,潘志军,李杭,等.抗生素骨水泥棒治疗交锁钉术后髓内感染.中华创伤杂志,2007,23(4):265-267.
36. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
2. Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol,1999,7:140?141.
3. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
4. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
5. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
6. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14(3):305?308.
7. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955?959.
8. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
9. Boxma H.Wound infections in fracture surgery. Thesis. University of Amsterdam. 1995
10. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
11. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453?458.
12. Bach AW, Hansen ST. Plates versus external fixation in severe open tibial shaft fractures. A randomized trial. Clin Orthop Relat Res,1989,24(4)1:89?94.
13. Worlock P, Slack R, Harvey L, Mawhinney R. The prevention of infection in open fractures: an experimental study of the effect of fracture stability. Injury,1994, 25(1):31?38.
14. Checketts R, Otterburn M, MacEachern G. Pin track infection: definition, incidence and prevention. Int J Orthop Trauma,1993,3(3):16?18.
15. Lee-Smith J, Santy J, Davis P, et al. Pin site management.Towards a consensus: part 1.J Orthop Nursing,2001,10(5):37?42.
16. Hargreaves DG, Pajkos A, Deva AK, et al. The role of biofilm formation in percutaneous Kirschner-wire fixation of radial fractures. J Hand Surg Br,2002, 27(4):365?368.
17. Maurer DJ, Merkow RL, Gustilo RB. Infection after intramedullary nailing of severe open tibial fractures initially treated with external fixation. J Bone Joint Surg Am,1989,71(6):835?838.
18. Court-Brown CM, Keating JF, McQueen MM. Infection after intramedullary nailing of the tibia. J Bone Joint Surg Br,1992,74(5):770?774.
19. Elek SD, Conen PE. The virulence of staphylococcus pyogenes for man. A study of the problems of wound infection. Br J Exp Pathol;1957,38(6):573?586.
20. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236?1244.
21. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother,1989,33(5):597?601.
22. Gristina A. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res,1994,298(1):106?118.
23. Merritt K, Dowd J. Role of internal fixation in infection of open fractures: Studies with Staphylococcus aureus and Proteus mirabilis. J Orthop Res,1987, 5(1):23?28.
24. Gristina A. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science,1987,237(4822):1588?1595.
25. Baier RE, Meyer AE, Natiella JR, et al. Surface properties determine bioadhesive outcomes: methods and results.J Biomed Mater Res,1984,18(4):327?355.
26. Ruoslahti E. Integrins as receptors for extracellular matrix. Hay ED (ed), Cell biology of extracellular matrix. 2nded. New York: Plenum Press,1991,343?363.
27. Francois P, Vaudaux P, Foster TJ, et al. Host-bacteria interactions in foreign bodyinfections. Infect Control Hosp Epidemiol;1996,17(8):514?520.
28. Patti JM, Hook M. Microbial adhesins recognizing extracellular matrix macromolecules. Curr Opin Cell Biol;1994,6(5):752?758.
29. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”. Injury, Int. J. Care Injured,2006,37(2):S37-S38.
30. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-981.
31. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
32.小林宏行.细菌菌膜的基础与临床[J].中国临床药理学杂志, 1999,15(4):299–301.
33. Drenkard E.Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes and Infection,2003,5(2):1213–1219.
34. Trampuz A, Gilomen A, Fluckiger U, et al. Treatment outcome of infections associated with internal fixation devices: Results from a 5-year retrospective study (1999-2003).45th ICAAC, American Society for Microbiology, December 16-19, 2005, Washington, DC; No. K-882.
35. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325?328.
36. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63?76.
37. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11):677?685.
38. Wilkinson BJ Biology. Crossley KB, Archer GL (eds),The Staphylococci in Human Diseases. New York: Churchill Livingston,1997,1?38.
39. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427?5433.
40. Howard BJ, Kloos WE Staphylococci. Howard BJ, Klass II J, Rubin SJ, et al (eds) Clinical and Pathogenic Microbiology. St Louis, Mo: The CV Mosby Co,1987,231?244.
41. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85?90.
42. Waldvogel FAStaphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489?1510.
43. Central Public Health Laboratory Surveillance of surgical site infection ? in English hospitals 1997?1999. UK.2000
44. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320?1325.
45. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis,2001,1(3):147?155.
46. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135?136.
47. Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material; J Infect Dis,1988,158(4):693?701.
48. Gross M, Cramton SE, Gotz F, et al. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun,2001 69(5):3423?3426.
49. Hoyle BD, Costerton JW. Bacterial resistance to antibiotics:the role of biofilms. Prog Drug Res,1991,37:91?105.
50. Caiazza NC, O’Toole GA. Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol,2003,185(10): 3214?3217.
51. Thakker M, Park JS, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteraemia model.Infect. Immun,1998,66(11):5183?5189.
52. Wilkinson BJ, Holmes KM. Staphylococcus aureus cell surface: capsule as a barrier to bacteriophage adsorption.Infect Immun,1979,23(2):549?552.
53. Projan SJ, Novick RP. The molecular basis of pathogenicity.Crossley KO, Archer GL(eds), The Staphylococci in Human Diseases. New York: Churchill Livingston, 1997,55?81.
54. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med,2005,202(2):209?215.
55. Proctor RA, van Langevelde P, Kristjansson M, et al. Persistent and relapsing infections associated with smallcolony variants of Staphylococcus aureus. Clin Infect Dis,1995,20(1):95?102.
56. von Eiff C, Proctor RA, Peters G. Small colony variants of Staphylococci: a link to persistent infections. Berl Munch Tierarztl Wochenschr,2000,113(9):321?325.
57. Quie PG. Microcolonies (G-variants) of Staphylococcus aureus. Yale J Biol Med, 1969,41(5):394?403.
58. Wise RI, Spink WW. The influence of antibiotics on the origin of small colonies (G variants)of Micrococcus pyogenes var.aureus. J Clin Invest,1954, 33(12):1611?1622.
59. von Eiff C, Heilmann C, Proctor RA, et al. A sitedirected Staphylococcus aureus hemB mutant is a smallcolony variant which persists intracellularly. J Bacteriol, 1997,179(15):4706?4712.
60. Proctor RA, Kahl B, von Eiff C, et al. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis,1998,27 (Suppl 1):68?74.
61. Salgado DR, Bozza FA, Pinto M, et al. (2002) Outbreak with small colony variants of methicillin-resistant Staphylococcus aureus in an ICU. 41. Interscience Conference on Antimicrobial Agents and Chemotherapy. 16.?19.12. 2001, Chicago, Ill.
62. Balwit JM, van Langevelde P, Vann JM, et al. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J Infect Dis,1994,170(4):1033?1037.
63. Baumert N, von Eiff C, Schaaff F, et al. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist,2002, 8(4):253?260.
64. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis,1987,155(3):581?585.
65. Koo SP, Bayer AS, Sahl HG, et al. Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect Immun,1996,64(3):1070?1074.
66. Musher DM, Baughn RE, Templeton GB, et al. Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J Infect Dis,1977,136(3):360?369.
67. Spearman P, Lakey D, Jotte S, et al. Sternoclavicular joint septic arthritis with small-colony variant Staphylococcus aureus. Diagn Microbiol Infect Dis,1996 26(1):13?15.
68. Von Eiff C, Peters G, Becker K. The small colony variant (SCV) concept—the role of staphylococcal SCVs in persistent infections.Injury, Int. J. Care Injured ,2006, 37(2), S26—S33.
69. Harris LG, Richards RG. Staphylococci and implant surfaces: a review. Injury, Int. J. Care Injured (2006) 37, S3—S14.
70. Hussain M, Becker K, von Eiff C, et al. Identification and characterization of a novel
38.5-Kilodalton cell surface protein of Staphylococcus aureus with extended-spectrum binding activity for extracellular matrix and plasma proteins.J Bacteriol,2001, 183(23):6778?6786.
71. Brotz H, Sahl HG. New insights into the mechanism of action of antibiotics-diverse biological effects by binding to the same molecular target. J Antimicrob Chemother,2000,46(1):1?6.
72. Kocianova S, Vuong C, Yao Y, et al. Key role of polygamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest, 2005,115(3):688?694.
73. Berger-B?chi B, McCallum N. State of the knowledge of bacterial resistanceInjury, Int. J. Care Injured,2006,37(2),S20—S25.
74. Sieradzki K, Leski T, Dick J, et al. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo:multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for therapy. J Clin Microbiol, 2003,41(4):1687?1693.
75. Hooper DC. Fluoroquinolone resistance among Grampositive cocci. Lancet Infect.Dis,2002,2(9):530?538.
76. Chopra I, O’Neill AJ, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat,2003,6(3):137?145.
77. Prunier AL, Malbruny B, Laurans M, et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis,2003,187(11):1709?1716.
78. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis,2002, 34(4):482?492.
79. Perichon B, Courvalin P. Update on vancomycin resistance.Int J Pract,2000, 54(4):250?254.
80. Baptista M, Depardieu F, Reynolds P, et al. Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci. Mol Microbiol, 1997,25(1):93?105.
81. Martin JF, Casqueiro J, Liras P. Secretion systems for secondary metabolites: how porducer cells send out messages of intercellular communication. Curr Opin Microbiol,2005,8(3):282?293.
82. Osborn AM, B?ltner D. When phage, plasmids, and transposons collide: genomic islands, and conjugative-and mobilizable-transposons as a mosaic continuum. Plasmid,2002,48(3):202?212.
83. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother,1994,38(7):1147?1451.
84. Hakenbeck R. Transformation in Streptococcus pneumoniae: mosaic genes and the regulation of competence. Res Microbiol,2000,151(6):453?546.
85. Ochsner1 PE, Hailemariam S. Histology of osteosynthesis associated bone infection. Injury, Int Care Injured,2006,37(2),S49—S58.
86. Burri C. Posttraumatic osteitis. 2nd ed. Bern, Stuttgart, Wien: Huber-Verlag. 1979
87. Rittmann WW, Perren SM (1974) Cortical bone healing after osteosynthesis and infection. Berlin, Heidelberg, New York: Springer-Verlag.
88. Sevitt S. Bone repair and fracture healing in man. Edinburgh: Churchill Livingstone. 1981
89. B?hm E, H?rster HG. [Histological progress studies of osteomyelitis ltreated locallywith gentamycin]. Aktuelle Probl Chir Orthop, 1979,12:182?186.
90. Ochsner PE, Brunazzi MG. Intramedullary reaming and soft tissue procedures in treatment of chronic osteomyelitis of long bones. Orthopedics,1994,17(5):433?440.
91. Ochsner PE, Sokhegyi A, Petralli C. [The value of computerized tomography in the assessment of chronic osteomyelitis.A radiological, histological and clinical correlation study]. ZOrthop Ihre Grenzgeb,1990,128(3):313?318.
92. Ochsner PE, Baumgart F, Kohler G. Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal Injury,1998, 29 (Suppl)2: B1?B10.
93. Baumgart F, Kohler G, Ochsner PE. The physics of heat generation during reaming of the medullary cavity. Injury,1998,29(Suppl 2): B11?B25.
94. B?hm E. [Chronic posttraumatic osteomyelitis. Morphology and pathogenesis]. Unfallheilkunde,1986,176. 6-8.
95. Andrej Trampuz1, Werner Zimmerli. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury,2006,37(2),S59—S66.
96. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
97. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153?162.
98. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647?649.
99. Spangehl MJ, Masri BA, O’Connell JX, et al (1999) Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am, 81(5):672?683.
100. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33Suppl 2:94?106.
101. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol,1999,37(10):3281?3290.
102. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prostheticcomponents in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2):628?631.
103. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414:69?88.
104. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.Radiology,2003,226(2):391-398.
105. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645-1654.
106. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249-256.
107. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA, 1998,279(19):1537-1541.
108. Giulieri SG, Graber P, Ochsner PE, et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection,2004, 32(4):222-228.
109. Widmer AF, Gaechter A, Ochsner PE, et al. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis, 1992,14(6): 1251-1253.
110. Pavoni GL, Falcone M, Baiocchi P, et al. Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience. J Chemother,2002,14(4):378-383.
111. Widmer AF, Frei R, Rajacic Z, et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis,1990, 162(1):96-102.
112. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc,2004,79(9):1137-1144.
113. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheralneuropathy associated with prolonged use of linezolid. Lancet Infect Dis,2004,4(8):528-531.
114. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy.Lancet,1996,347(9015):1579-1582.
115. Charnley J (1970) Acrylic cement in orthopedic surgery.Edinburgh and London: E&S Livingstone, 118-125.
116. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant- related infections by local application of antibiotics.Injury,2006,37, S95-S104.
117. Buchholz HW, Elson RA, Engelbrecht E, et al. Management of deep infection of total hip replacement. J Bone Joint Surg Br,1981,63-B(3):342-353.
118. Espehaug B, Engesaeter LB, Vollset SE et al. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg BR,1997, 79(4):590-595.
119. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
120. Tunney MM, Ramage G, Patrick S et al. Antimicrobial susceptibility of bacteria isolated from orthopedic implants following revision hip surgery. Antimicrob Agents Chemother,1998,42(11):3002-3005.
121. Kendall RW, Duncan CP, Smith JA et al. Persistence of bacteria on antibiotic loaded acrylic depots: A reason for caution. Clin Orthop,1996,329:273-280.
122. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
123. Klemm K (1979) [ Gentamicin PMMA-beads in treating bone and soft tissue infections (author’s transl)] Zentralbl Chir, 104(14):934-942.
124. Wahlig H, Dingeldein E, Bergmann R et al. The release of gentamicin from polymethlymethacrylate beads. An experimental and pharmacokinetic study. J Bone Joint Surg Br,1978,60-B(2):270-275.
125. Salvati EA, Callaghan JJ, Brause BD et al. Reimplantation in infection. Elution of gentamicin from cement and beads. Clin Orthop,1986,207:83-93.
126. Patzakis MJ, Mazur K, Wilkins J et al. Septopal beads and autogenous bone grafting for bone defects in patients with chronic osteomyelitis. Clin Orthop RelatRes,1993,295:112–118.
127. Calhoun JH, Henry SL, Anger DM et al. The treatment of infected nonunions with gentamicin-polymethylmethacrylate antibiotic beads. Clin Orthop Relat Res,1993, 295:23–27.
128. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
129. Riegels-Nielsen P, Espersen F, Holmich LR et al. Collagen with gentamicin for prophylaxis of postoperative infection. Staphylococcus aureus osteomyelitis studied in rabbits. Acta Orthop Scand,1995,66(1):69-72.
130. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
131. Ostermann PA, Henry SL, Seligson D. The role of local antibiotic therapy in the management of compound fractures. Clin Orthop Relat Res,1993,295:102-111.
132. Hettfleisch J, Schottle H (1993) [Local preventive antibiotic treatment in intramedullary nailing with gentamicin impregnated biomaterials] Aktuelle Traumatol, 23(2):68-71.
133. Eklund AM, Valtonen M, Werkkala KA. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery. J Hosp Infect,2005,59(2):108?112.
134. Friberg O, Svedjeholm R, Soderquist B et al. Local gentamicin reduces sternal wound infections after cardiac surgery: a randomised controlled trial. Ann Thorac Surg,2005, 79(1):153?162.
135. Ascherl R, Stemberger A, Lechner F et al. [Treatment of chronic osteomyelitis with a collagen-antibiotic compound–preliminary report.] Unfallchirurgie,1986, 12(3):125– 127.
136. Sorensen TS, Sorensen AI, Merser S. Rapid release of gentamicin from collagen sponge. In vitro comparison with plastic beads. Acta Orthop Scand,1990, 61(4): 353–356.
137. Mehta S, Humphrey JS, Schenkman DI et al. Gentamicin distribution from a collagencarrier. J Orthop Res,1996,14(5):749–754.
138. Walenkamp GHIM, Karsemaker S. Pharmacokinetics of two gentamicin collagen fleeces in animal experiments. Walenkamp GHIM (ed) Biomaterials in Surgery. Stuttgart,New York: Georg Thieme Verlag,1998,18–20.
139. Moser A. Comparative human pharmacokinetics of two gentamicin-containing collagen carriers. Walenkamp GHIM(ed) Biomaterials in Surgery. Stuttgart, New York: GeorgThieme Verlag,1998,21–24.
140. Humphrey JS, Mehta S, Seaber AV et al. Pharmacokinetics of a degradable drug delivery system in bone. Clin Orthop Relat Res,1998,349:218–224.
141. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
142. Mader JT, Calhoun J, Cobos J (1997) In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother,41(2):415–418.
143. Frommelt L.Principles of systemic antimicrobial therapy in foreign material associated infection in bone tissue,with special focus on periprosthetic infection. Injury,2006, 37(2),S87-S94.
144. Mader JT, Adams KR. Experimental osteomyelitis. Schlossberg D (ed) Orthopedic Infection. New York: Springer Verlag,1988,39?48.
145. Bengtson S, Knutson K. The infected knee arthroplasty.A 6-year follow-up of 357 cases. Acta Orthop Scand,1991,62(4):30111.
146. Tattevin P, Cremieux AC, Pottier P, et al. Prosthetic joint infection: When can prosthesis salvage be considered? Clin Infect Dis,1999,29(2):292?295.
147. Brause BD. Infection with prostheses in bone and joint. Mandell GL, Bennet JE, Dolin R (eds) Principles and practice of infectious Diseases. 5th ed. Philadelphia: Churchhill Livingstone,2000,1196?1200.
148. Goulet JA, Pellicci PM, Brause BD, et al. Prolonged suppression of infection in total hip arthroplasty. J Arthroplasty,1988,3(2):109?116.
149. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645?1654.
150. Mella-Schmidt C, Steinbrink K. [Value of irrigationsuction drainage in the treatmentof early infection of joint implants]. Chirurg,1989,60(11):791?794.
151. Robbins GM, Masri BA, Garbuz DS, et al. Primary Total hip arthroplasty after infection.J Bone Joint Surg Am,2001,83(4):601?614.
152. Frommelt L.[Guidelines on antimicrobial therapy in situations of periprosthetic THR infection]. Orthop?de,2004,33(7):822?826.
153. Langlais F, Lambotte JC, Thomazeau H. Treatment of infected hip replacement. Lemaire R, Herom F, Scott J, (eds),European Instructional Course Lectures Vol 6. London: The British Society of Bone and Joint Surgery,2003,158?167.
154. Haleem AA, Berry DJ, Hanssen AD. Mid-term to longterm followup of two-stage reimplantation for infected total knee arthroplasty. Clin Orthop Relat Res,2004, 428:35–39.
155. Henderson MH Jr, Booth RE Jr. The use of an antibioticimpregnated spacer block for revision of the septic total knee arthroplasty. Semin Arthroplasty,1991,2(1): 34–39.
156. Nazarian DG, de Jesus D, McGuigan F et al. A twostage approach to primary knee arthroplasty in the infected arthritic knee. J Arthroplasty,2003,18(7):16–21.
157. Wilde AH, Ruth JT. Two-stage reimplantation in infected total knee arthroplasty. Clin Orthop Relat Res,1988,236:23–35.
158. Calton TF, Fehring TK, Griffin WL. Bone loss associated with the use of spacer blocks in infected total knee arthroplasty. Clin Orthop Relat Res,1997, 345:148–154.
159. Hsieh PH, Shih CH, Chang YH et al. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J Bone Joint Surg Am,2004,86(9):1989?1997.
160. Schlegel U, Perren SM.Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection.Injury,2006,37(2), S67—S73
161. Melcher G, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. J Bone Joint Surg Br,1994,76(6):955?959.
162. Arens S, Eijer H, Schlegel U, et al. Influence of the design for fixation implants on local infection: Experimental study of dynamic compression plates versus point contact fixators in rabbits. J Orthop Trauma,1999,13(7):470?476.
163. Horn J, Schlegel U, Krettek C, et al. Infection resistance of unreamed solid, hollowslotted and cannulated intramedullary nails: an in-vivo experimental comparison. J Orthop Res,2005,23(4):810?815.
164. Hauke C, Schlegel U, Melcher GA, et al. Local infection in relation to different implant materials. An experimental study using stainless steel and titanium solid, unlocked, intramedullary nails in rabbits. Orthop Trans,1997,21:835?836.
165. Melcher GA, Metzdorf A, Schlegel U, et al. Influence of reaming versus nonreaming in intramedullary nailing on local infection rate: Experimental investigation in rabbits. J Trauma,1995,39(6):1123?1128.
166. Metzdorf A (1996) Einfluss der Markraumbohrung auf die Entstehung eines lokalen Infektes. Universit?t Würzburg. Dissertation.
167. Arens S, Schlegel U, Printzen G, et al. Influence of materials for fixation implants on local infection. An experimental study of steel versus titanium DCP in rabbits. J Bone Joint Surg Br,1996,78(4):647?651.
168. Eijer H, Arens S, Schlegel U, et al. Einfluss des Implantat-Designs auf die lokale Infektentstehung. Tierexperimentelle Untersuchung von DC-Platten und Point-Contact Fixateuren. Springer Verlag, Berlin. Hefte zu: Der Unfallchirurg, 1997,268, 855?856.
169. Mainil-Varlet P, Hauke C, Printzen G, et al. (1999) Polylactide implants for internal fixation of bacterially contaminated fractures. Stein H, Suk SE-II, Ping-Chung Leung (eds) SIROT 1999. Sydney: Freund Publishing House, 21?27.
170. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
171. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
172. Lucke M, Schmidmaier G, Sadoni S et al. Gentamicin coating of metal implants reduces implant-related osteomyelitis in rats. Bone,2003,32(5):521?531.
173. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2),S105-S112.
174. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000,282:362?363.
175. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59-S66.
176. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
177. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249?256.
178. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA,1998, 279(19):1537?1541.
179. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res,1999,(360):22?29.
180. Trampuz A, Gilomen A, Fluckiger U, et al. (2005) Treatment outcome of infections associated with internal fixation devices: Results from a 5-year retrospective study (1999-2003).45th ICAAC, American Society for Microbiology, December 16-19, 2005, Washington, DC; No. K-882.
181. Peter EO, Martin M, Christian P. Infection after osteosynthesis: a summary of the scientific presentations at the annual Swiss AO meeting 2005 in Liestal Injury,2006,37(2),S117-S119.
182. Lau YS, Wang W, Sabokbar A, et al.Staphylococcus aureus capsular material promotes osteoclast formation.Injury,2006,37(2),S41-S48.
183. Stallmann HP, Faber C, Amerongen AVN, et al.Antimicrobial peptides: review of their application in musculoskeletal infections Injury,2006,37(2),S34-S40.
184. Neut D, van de Belt H, Stokroos I, et al. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother,2001,47(6):885?891.
185. Helmerhorst EJ, Breeuwer P, van’t Hof W, et al. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem,1999, 274:7286?7291.
186. Helmerhorst EJ, Troxler RF, Oppenheim FG. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci USA, 2001,98:14637?14642.
187. Helmerhorst EJ, van’t Hof W, Breeuwer P, et al.Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation. J Biol Chem,2001,276(8):5643?5649.
188. Helmerhorst EJ, Murphy MP, Troxler RF, et al. Characterization of the mitochondrial respiratory pathways in Candida albicans. Biochim Biophys Acta,2002, 1556:73?80.
189. Zasloff M. Antimicrobial peptides of multicellular organisms.Nature,2002, 415(6870):389?395.
190. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis,2001,1(3):156?164.
191. Nibbering PH, Ravensbergen E, Welling MM, et al.Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun,2001,69(3):1469?1476.
192. Faber C, Hoogendoorn RJ, Stallmann HP, et al. In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemothe, 2004,54(6):1078?1084.
193. Faber C, Stallmann HP, Lyaruu DM, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother,2005, 49(6):2438?2444.
194. Stallmann HP, Faber C, Bronckers AL, et al. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother,2004,54(2):472?476.
195. Helmerhorst EJ, Hodgson R, van‘t Hof W, et al. The effects of histatin-derived basic antimicrobial peptides on oral biofilms. J Dent Res,1999,78(6):1245?1250.
196. Lupetti A, Paulusma-Annema A, Welling MM, et al.Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother,2000, 44(12):3257?3263.
197. Stallmann HP, Faber C, Bronckers AL, et al. Histatin and lactoferrin derived peptides: Antimicrobial properties and effects on mammalian cells. Peptides,2005, 26(12):2355?2359.
198. Hancock RE. Peptide antibiotics. Lancet,1997,349(9049):418?422.
199. Ganz T. Fatal attraction evaded. How pathogenic bacteria resist cationic polypeptides. J Exp Med,2001,193(9):F31?F34.
200. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev,2003,55(1):27?55.
201. Faber C, Stallmann HP, Lyaruu DM, et al. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J Antimicrob Chemother,2003,51(6):1359?1364.
202. Stallmann HP, Faber C, Slotema ET, et al. Continuousrelease or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes. J Antimicrob Chemother,2003,52(5):853?855.
203. Bartlett KH, McCray PB Jr, Thorne PS. Novispirin G10-induced lung toxicity in a Klebsiella pneumoniae infection model. Antimicrob Agents Chemother,2003, 47(12):3901?3906.
204. Lupetti A, Nibbering PH, Welling MM, et al. Radiopharmaceuticals: new antimicrobial agents. Trends Biotechnol,2003,21(2):70?73.
205. Lupetti A, Paulusma-Annema A, Welling MM, et al. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob Agents Chemother,2003,47(1):262?267.
206. Nekhotiaeva N, Elmquist A, Rajarao GK, et al. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J,2004,18(2):394?396.
1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
2. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
3. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
4. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
5. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
6. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”.Injury,2006,37(2):S37-S38.
7. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-1198.
8. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
9. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics.Injury,2006,37(2), S95—S104.
10. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
11. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
12. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
13. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin frombiodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
14. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
15. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
16. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
17. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review.Injury, 2006,37(2): S105-S112.
18. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
1. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
2. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
3. Andrej Trampuz1, Werner Zimmerli. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury,2006,37(2),S59-S66.
4. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645-1654.
5. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249-256.
6. Giulieri SG, Graber P, Ochsner PE, et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection,2004, 32(4):222-228.
7. Pavoni GL, Falcone M, Baiocchi P, et al. Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience. J Chemother,2002,14(4):378-383.
8. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc,2004,79(9):1137-1144.
9. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics.Injury,2006,37(2): S95—S104.
10. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
11. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
12. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
13. Schlegel U, Perren SM. Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection.Injury,2006,37,S67-S73.
14. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2), S105-S112.
15. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59-S66.
16. Neut D, van de Belt H, Stokroos I, et al. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother,2001,47(6):885?891.
17. Stallmann HP, Faber C, Amerongen AVN, et al.Antimicrobial peptides: review of their application in musculoskeletal infections. Injury,2006,37(2),S34-S40.
18. Stallmann HP, Faber C, Bronckers AL, et al. Histatin and lactoferrin derived peptides: Antimicrobial properties and effects on mammalian cells. Peptides,2005,26(12): 2355?2359.
19. Faber C, Hoogendoorn RJ, Stallmann HP, et al. In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemother, 2004,54(6):1078?1084.
20. Faber C, Stallmann HP, Lyaruu DM, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother,2005, 49(6):2438?2444.
2. Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol,1999,7:140-141.
3. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621-643.
4. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949-954.
5. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am;1990,72(2):299-304.
6. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14:305-308.
7. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955-959.
8. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
9. Boxma H.Wound infections in fracture surgery. Thesis. University of Amsterdam. 1995
10. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia, 2001,56(2): 201-206.
11. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453-458.
12. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”. Injury, Int. J. Care Injured,2006,37(2):S37-S38.
13. Bach AW, Hansen ST. Plates versus external fixation in severe open tibial shaft fractures. A randomized trial. Clin Orthop Relat Res,1989,241(4):89-94.
14. Worlock P, Slack R, Harvey L, Mawhinney R. The prevention of infection in open fractures: an experimental study of the effect of fracture stability. Injury, 1994,25(1):31-38.
15. Checketts R, Otterburn M, MacEachern G. Pin track infection: definition, incidence and prevention. Int J Orthop Trauma,1993,3(3): 6-18.
16. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299-304.
17. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153-162.
18. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647-649.
19. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325-328.
20. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63-76.
21. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11):677-685.
22. Wilkinson BJ Biology. Crossley KB, Archer GL (eds),The Staphylococci in Human Diseases. New York: Churchill Livingston,1997,1-38
23. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427-5433.
24. Howard BJ, Kloos WE Staphylococci. Howard BJ, Klass II J, Rubin SJ, et al (eds) Clinical and Pathogenic Microbiology. St Louis, Mo: The CV Mosby Co,1987,231-244.
25. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85-90.
26. Waldvogel FA.Staphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489-1510.
27. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am;1985,67(8):1236-1244.
28. Central Public Health Laboratory Surveillance of surgical site infection-in English hospitals 1997-1999. UK.2000.
29. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320-1325.
30. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis,2001,1(3):147-155.
31. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135-136.
32. Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material; J Infect Dis,1988,158(4):693-701.
33. Spangehl MJ, Masri BA, O’Connell JX, et al. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am,1999,81(5):672-683.
34. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33(Suppl 2):94-106.
35. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol, 1999,37(10):3281-3290.
36. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2): 628-631.
37. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414(9):69?88.
38. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
39. Ajioka M, Suizu H , Higuchi C , et al .Aliphatic polyesters and their copolymers synthesized through direct condensation polymerization. Polymer Degradation and Stability,1998,59(2) :137-143.
40. Schindler A, Harper D. Polylactide:Ⅱ.Viscosity-molecular weight relationships and unperturbed chain dimensions.Journal of Polymer Science:Polymer Chemistryition.1979,17∶2593-2599
41. Majola A ,Vainionapaa S ,Vihtonen K,et al . Absorption , bicompatibility and fixation properties of polylactic acid in bone tissue : an experimental study in rats. Clinical Orthopaedics and Related Research, 1991,268(6):260-269.
42. Rozema FR ,Bos R RM,Pennings AJ ,et al.Poly(l-lactide) implants in repair of defects of the orbital floor :an animal study. Journal of Oral and Maxillofacial Surgery,1990,48(12):1305-1309.
43. Bos RRM,Rozema FR,Boering G,et al.Degradation of and tissue reaction to biodegradable poly (l-lactide) for use as internal fixation of fractures:A study in rats.Biomaterials,1991,12(1) :32-36.
44. Tormala P ,Vaiionpaa S , Kilpikari J ,et al.The effects of fiber reinforcement and gold plating on the flexual and tensile strength of PGA/PLA copolymer materials in vitro.Biomaterials,1987,8(1) 42-45.
45. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
46. Lucke M, Schmidmaier G, Sadoni S et al. Gentamicin coating of metal implants reduces implant-related osteomyelitis in rats. Bone,2003,32(5):521?531.
47. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2),S105—S112.
48. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
1. Kulkarni RK,Pani KC,Neuman C,et al.Polylactic acid for Surgery Implants.Arches Surge,1966,93(5):839-843.
2.胡培战,吴兰亭,杨士林.医用生物降解材料-聚乳酸及其共聚物.生物医学工程杂志,1993,10(2):183-193.
3.唐家驹,潘长江,洪玮,等.大黄素/聚乳酸物复合薄膜的制备及抗凝血研究.2006,8(37):1312-1314.
4. Schmidmaier G, Wildemann B, Bail H,et al.Local Application of Growth Factors (Insulin-Like Growth Factor-1 and Transforming Growth Factor-b1) From a Biodegradable Poly(D,L-lactide) Coating of Osteosynthetic Implants Accelerates Fracture Healing in Rats.Bone, 2001,28(4):341–350.
5. Lucke M, Wildemann B,Sadoni S,et al.Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model.Bone,2005, 36(5):770-778.
6.胡洪国,田丰月,闫玉华,等.聚乳酸及其共聚物的国内外研究现状和进展.国外建材科技,2000,21(1):1-4.
7. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85-90.
8. Waldvogel FAStaphylococcus aureus (including toxic shock syndrome). Mandell GL,Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York: Churchill Livingston,1990, 1489-1510.
9. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325-328.
10. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236-1244.
11. Sievert DM, Boulton ML, Stoltman G,et al. Staphylococcus aureus resistant to Vancomycin-United States.2002.MMWR, 2002,51(26):565-569.
12. Bo Shopsin, Barry NK. Molecular epidemiology of methicillin resistant Staphylococcus aureus. Emerg Infect Dis,2001,7(2):323-326.
13.徐小平,高霞,池晓霞,等.葡萄球菌属和肠球菌属耐药性监测研究.中华医院感染学杂志,2006,16(3):324-326.
14.汪复,朱德妹.上海地区细菌耐药性监测[J].中国抗感染化疗杂志, 2002, 2(1):129-131.
15.申正义,孙自镛,王洪波.湖北地区临床细菌耐药性监测.中华医院感染学杂志,2002,12(2):91-94.
16.马越,陈鸿波,李景云,等. 1999～2000年北京和湖北地区金葡菌耐药性分析.中国临床药理学杂志,2002,18(3):185-187.
17. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320?1325.
18. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135?136.
19. Von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11): 677?685.
20. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med,2005,202(2):209?215.
21. Nada T ,Ichiyama S, Osada Y, et al. Comparison of DNA fingerprinting by PFGE and PCR-RFLP of the coagulase gene to distinguish MRSA isolates. J HospInfect,1996,32(4):305-310.
22. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Stap hylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 2000,44(6):1549-1561.
23. Matsuhashi M , Song MD, Ishino F, et al. Molecular cloning of the gene of a penicillin binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol, 1986,167(3):975-986.
24. Hurlimann-Dalei RL, Ryffel C, Kayser FH, et al. Survey of the methicillin resistance-associated genes mecA, mecR 1-mecI,and femA-femB in clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother,1992, 36(12): 2617-2625.
25. Suzuki E, Hiramatsu K, Yokot T. Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for mecA gene distribution. Antimicrob Agents Chem other,1992,36(2):429-435.
26. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-1198.
27. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
28. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury,2006,37(2), S95—S104.
29. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand, 2003,74(6):644-651.
30. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br, 2005,87(2):272-276.
31. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
32. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
33. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
34. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review.Injury, 2006,37(2),S105—S112.
35. Lucke M, Schmidmaier G, Wildemann B,et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
36. Kalicke T, Schierholz J, Schlegel U, et al. Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and in vivo study. J Orthop Res, 2006,24(8): 1622-1640.
37. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
38. Pitt CG, Gratzl MM, Kimmel GL,et al. Aliphatic polyesters II. The degradation of poly(D,Llactide), poly(epsilon-caprolactone) and their copolymers in vivo.Biomaterials, 1981,2(4), 215–220.
39. Cutright DE, Perez B, Beasley JD,et al.Degradation rates of polymers and copolymers of polylactic and polyglycolic acids.Oral Surgery,Oral Medicine,Oral Pathology,1974, 37(1), 142–152.
40. Kohn J,Langer R. Bioresorbable and bioerodible materials. In Biomaterials Science (Ratner BD, Hoffman AS,Schoen FJ), 1996,64–73.
41. Richards RG, Harris LG,Schneider E,et al.Antiseptics and antibiotics on implants. Injury,2006,37(2):S113—S116.
1. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
2. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
3. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453?458.
4. Elek SD, Conen PE. The virulence of staphylococcus pyogenes for man. A study of the problems of wound infection. Br J Exp Pathol,1957,38(6):573?586.
5. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236?1244.
6. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother,1989,33(5):597?601.
7. Gristina A. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res,1994,298(1):106?118.
8. Merritt K, Dowd J. Role of internal fixation in infection of open fractures: Studies with Staphylococcus aureus and Proteus mirabilis. J Orthop Res,1987, 5(1):23?28.
9. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
10. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
11. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14(3):305?308.
12. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955?959.
13. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization ofStaphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325?328.
14. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63?76.
15. Elek S.Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85?90.
16. Waldvogel FA.Staphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489?1510.
17. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427?5433.
18. Spangehl MJ, Masri BA, O’Connell JX, et al.Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am,1999,81(5):672?683.
19. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
20. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153?162.
21. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647?649.
22. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33Suppl 2:94?106.
23. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol,1999,37(10): 3281?3290.
24. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2):628?631.
25. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414:69?88.
26. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.Radiology,2003,226(2):391-398.
27. Ochsner1 PE, Hailemariam S. Histology of osteosynthesis associated bone infection. Injury, Int Care Injured,2006,37(2),S49—S58.
28. Burri C (1979) Posttraumatic osteitis. 2nd ed. Bern, Stuttgart, Wien: Huber-Verlag.
29. Rittmann WW, Perren SM (1974) Cortical bone healing after osteosynthesis and infection. Berlin, Heidelberg, New York: Springer-Verlag.
30. Sevitt S (1981) Bone repair and fracture healing in man. Edinburgh: Churchill Livingstone.
31. B?hm E, H?rster HG [Histological progress studies of osteomyelitis ltreated locally with gentamycin]. Aktuelle Probl Chir Orthop,1979,12:182?186.
32. Ochsner PE, Brunazzi MG. Intramedullary reaming and soft tissue procedures in treatment of chronic osteomyelitis of long bones. Orthopedics,1994,17(5):433?440.
33. Ochsner PE, Sokhegyi A, Petralli C. [The value of computerized tomography in the assessment of chronic osteomyelitis.A radiological, histological and clinical correlation study]. ZOrthop Ihre Grenzgeb,1990,128(3):313?318.
34. Ochsner PE, Baumgart F, Kohler G. Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal Injury,1998, 29 (Suppl)2: B1?B10.
35. Baumgart F, Kohler G, Ochsner PE. The physics of heat generation during reaming of the medullary cavity. Injury,1998,29(Suppl 2): B11?B25.
36. B?hm E. [Chronic posttraumatic osteomyelitis. Morphology and pathogenesis]. Unfallheilkunde,1986,176.
1. Clifford RP (2000) Open fractures. Rüedi TP, Murphy WM(eds), AO Principles of Fracture Management. AO Publishing,Stuttgart New York: Thieme-Verlag: 621-643.
2. Bagnoa A, Genovesea M, Luchinia A,et al.Contact prolometry and correspondence analysis to correlate surface properties and cell adhesion in vitro of uncoated and coated Ti and Ti6Al4V disks. Biomaterials,2004,25:2437–2445.
3. Gollwitzer H, Ibrahim K, Meyer H, et al.Antibacterial poly(D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother,2004,51(3):585-591.
4. Kalicke T, Schierholz J, Schlegel U, et al. Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: An in vitro and in vivo study. J Orthop Res , 2006,24:1622-1640.
5. Schmidmaier1 G, Lucke M, Wildemann1 B,et al.Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37,S105—S112.
6. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59—S66.
7. Darouiche RO. Treatment of infections associated with surgical implants. N Engl JMed,2004,350(14):1422?1429.
8. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249?256.
9. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA,1998, 279(19):1537?1541.
10. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res,1999,(360):22?29.
11. Schlegel U, Perren SM. Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection. Injury,2006,37(2),S67—S73.
12. Melcher G, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. J Bone Joint Surg Br,1994,76(6):955?959.
13. Arens S, Eijer H, Schlegel U, et al. Influence of the design for fixation implants on local infection: Experimental study of dynamic compression plates versus point contact fixators in rabbits. J Orthop Trauma,1999, 13(7):470?476.
14. Horn J, Schlegel U, Krettek C, et al. Infection resistance of unreamed solid, hollow slotted and cannulated intramedullary nails: an in-vivo experimental comparison. J Orthop Res,2005,23(4):810?815.
15. Hauke C, Schlegel U, Melcher GA, et al. Local infection in relation to different implant materials. An experimental study using stainless steel and titanium solid, unlocked, intramedullary nails in rabbits. Orthop Trans,1997,21:835?836.
16. Melcher GA, Metzdorf A, Schlegel U, et al. Influence of reaming versus nonreaming in intramedullary nailing on local infection rate: Experimental investigation in rabbits. J Trauma,1995,39(6):1123?1128.
17. Metzdorf A (1996) Einfluss der Markraumbohrung auf die Entstehung eines lokalen Infektes. Universit?t Würzburg. Dissertation.
18. Arens S, Schlegel U, Printzen G, et al. Influence of materials for fixation implants on local infection. An experimental study of steel versus titanium DCP in rabbits. J BoneJoint Surg Br,1996,78(4):647?651.
19. Eijer H, Arens S, Schlegel U, et al. Einfluss des Implantat-Designs auf die lokale Infektentstehung. Tierexperimentelle Untersuchung von DC-Platten und Point-Contact Fixateuren. Springer Verlag, Berlin. Hefte zu: Der Unfallchirurg,1997,268, 855?856.
20. Magnan B, Regis D, Biscaglia R, et al. Preformed acrylic bone cement spacer loaded with antibiotics: use of two-stage procedure in 10 patients because of infected hips after total replacement.Acta Orthop Scand, 2001, 72(6): 591-594.
21. Langlais F. Antibiotic-loaded bone cements: from laboratory studies clinical evaluation. Bull A cad Natl Med, 2004,188(6):1011-1022.
22. Taggart T, Kerry RM , Norman P, et al.The use of vancomycin-impregnated cement beads in the management of infection of prosthetic joints. J Bone Joint Surg (Br),2002,84(1): 70-72.
23.杨静,段宏,裴福兴.髋关节置换后慢性感染伴窦道形成的手术治疗.中华骨科杂志,2001,21(12): 741-744.
24.王爱民,王子明,唐桂阳,等.万古霉素骨水泥在感染人工髋关节翻修中作用的实验研究与临床观察。中华创伤骨科杂志,2004,6(6):603-607.
25.王子明,王爱民,唐桂阳.兔人工股骨头置换后感染模型的建立及万古霉素-聚甲基丙烯酸甲酯的预防作用.中华创伤杂志,2002,18(11):667-670.
26. Cabanela ME.Open cancellous bone grafting of infected bone defects.Orthop Clin North Am,1984,15(3):427-440.
27. Patzakis MJ,Scilaris TA,Chon J,et al.Result of bone grafting for infected tibial nonunion. Clin Orthop,1995,315(6):192-198.
28. Emami A,Mjoberg B,Larsson S.Infected tibial nonunion.Good result after open cancellous bone grafting in 37 cases.Acta Orthop Scand,1995,66(5):447-451.
29. Esterhal JL,Sennett B,Gelb H,et al.Treatment of chronic osteomylitis complicating nonunion and segemental defects of the tibial with open cancellous bone graft, posterolateral bone graft,and soft–tissue tranfer.J trauma,1990,30(7):49-54.
30. Green SA,Dlabal TA.The open bone graft for septic nonunion. Clin Orthop,1983,180(11):117-124.
31. Papineau LJ,Alfageme A.Chronic osteomylitis of long bone resection and bone grafting with delayed skin closure.J Bone J Surg(Br), 1976,58:138.
32.刘德全,张伯松,刘洪波,等.一期开放松质骨植骨治疗感染性骨缺损的实验研究.中华创伤骨科杂志,2004,6(12):1370-1373.
33. Patzakis MJ, Wilkins J, Wiss DA. Infected following intramedullary nailing of long bones: diagnosis and manegement. Clin Orthop,1986,212(11):182-191.
34. Ueng WN,Shih CH.Manegement of infected tibial intramedullary nailing using an organized treatment protocal.J Formos Med Assoc,1992,91(9):879-885.
35.郑强,潘志军,李杭,等.抗生素骨水泥棒治疗交锁钉术后髓内感染.中华创伤杂志,2007,23(4):265-267.
36. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
2. Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol,1999,7:140?141.
3. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
4. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
5. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
6. Mahan J, Seligson D, Henry SL, et al. Factors in pin tract infections. Orthopedics, 1991,14(3):305?308.
7. Melcher GA, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits.J Bone Joint Surg Br,1994,76(6):955?959.
8. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
9. Boxma H.Wound infections in fracture surgery. Thesis. University of Amsterdam. 1995
10. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
11. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am,1976,58(4):453?458.
12. Bach AW, Hansen ST. Plates versus external fixation in severe open tibial shaft fractures. A randomized trial. Clin Orthop Relat Res,1989,24(4)1:89?94.
13. Worlock P, Slack R, Harvey L, Mawhinney R. The prevention of infection in open fractures: an experimental study of the effect of fracture stability. Injury,1994, 25(1):31?38.
14. Checketts R, Otterburn M, MacEachern G. Pin track infection: definition, incidence and prevention. Int J Orthop Trauma,1993,3(3):16?18.
15. Lee-Smith J, Santy J, Davis P, et al. Pin site management.Towards a consensus: part 1.J Orthop Nursing,2001,10(5):37?42.
16. Hargreaves DG, Pajkos A, Deva AK, et al. The role of biofilm formation in percutaneous Kirschner-wire fixation of radial fractures. J Hand Surg Br,2002, 27(4):365?368.
17. Maurer DJ, Merkow RL, Gustilo RB. Infection after intramedullary nailing of severe open tibial fractures initially treated with external fixation. J Bone Joint Surg Am,1989,71(6):835?838.
18. Court-Brown CM, Keating JF, McQueen MM. Infection after intramedullary nailing of the tibia. J Bone Joint Surg Br,1992,74(5):770?774.
19. Elek SD, Conen PE. The virulence of staphylococcus pyogenes for man. A study of the problems of wound infection. Br J Exp Pathol;1957,38(6):573?586.
20. Petty W, Spanier S, Shuster JJ, et al. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am,1985 67(8):1236?1244.
21. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother,1989,33(5):597?601.
22. Gristina A. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res,1994,298(1):106?118.
23. Merritt K, Dowd J. Role of internal fixation in infection of open fractures: Studies with Staphylococcus aureus and Proteus mirabilis. J Orthop Res,1987, 5(1):23?28.
24. Gristina A. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science,1987,237(4822):1588?1595.
25. Baier RE, Meyer AE, Natiella JR, et al. Surface properties determine bioadhesive outcomes: methods and results.J Biomed Mater Res,1984,18(4):327?355.
26. Ruoslahti E. Integrins as receptors for extracellular matrix. Hay ED (ed), Cell biology of extracellular matrix. 2nded. New York: Plenum Press,1991,343?363.
27. Francois P, Vaudaux P, Foster TJ, et al. Host-bacteria interactions in foreign bodyinfections. Infect Control Hosp Epidemiol;1996,17(8):514?520.
28. Patti JM, Hook M. Microbial adhesins recognizing extracellular matrix macromolecules. Curr Opin Cell Biol;1994,6(5):752?758.
29. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”. Injury, Int. J. Care Injured,2006,37(2):S37-S38.
30. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-981.
31. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
32.小林宏行.细菌菌膜的基础与临床[J].中国临床药理学杂志, 1999,15(4):299–301.
33. Drenkard E.Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes and Infection,2003,5(2):1213–1219.
34. Trampuz A, Gilomen A, Fluckiger U, et al. Treatment outcome of infections associated with internal fixation devices: Results from a 5-year retrospective study (1999-2003).45th ICAAC, American Society for Microbiology, December 16-19, 2005, Washington, DC; No. K-882.
35. Barth E, Myrvik QM, Wagner W, et al. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials,1989,10(5):325?328.
36. von Eiff C, Proctor RA, Peters G. Coagulase-negative staphylococci. Pathogens have major role in nosocomial infections. Postgrad Med,2001,110(4):63?76.
37. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis,2002,2(11):677?685.
38. Wilkinson BJ Biology. Crossley KB, Archer GL (eds),The Staphylococci in Human Diseases. New York: Churchill Livingston,1997,1?38.
39. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun,1999,67(10):5427?5433.
40. Howard BJ, Kloos WE Staphylococci. Howard BJ, Klass II J, Rubin SJ, et al (eds) Clinical and Pathogenic Microbiology. St Louis, Mo: The CV Mosby Co,1987,231?244.
41. Elek S Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci,1956,65(3):85?90.
42. Waldvogel FAStaphylococcus aureus (including toxic shock syndrome). Mandell GL, Douglas RG, Bennett JE (eds),Principles and practice of infectious disease 3rd ed. New York:Churchill Livingston,1990,1489?1510.
43. Central Public Health Laboratory Surveillance of surgical site infection ? in English hospitals 1997?1999. UK.2000
44. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg,1997,132(12):1320?1325.
45. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis,2001,1(3):147?155.
46. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997,40(1):135?136.
47. Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material; J Infect Dis,1988,158(4):693?701.
48. Gross M, Cramton SE, Gotz F, et al. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun,2001 69(5):3423?3426.
49. Hoyle BD, Costerton JW. Bacterial resistance to antibiotics:the role of biofilms. Prog Drug Res,1991,37:91?105.
50. Caiazza NC, O’Toole GA. Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol,2003,185(10): 3214?3217.
51. Thakker M, Park JS, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteraemia model.Infect. Immun,1998,66(11):5183?5189.
52. Wilkinson BJ, Holmes KM. Staphylococcus aureus cell surface: capsule as a barrier to bacteriophage adsorption.Infect Immun,1979,23(2):549?552.
53. Projan SJ, Novick RP. The molecular basis of pathogenicity.Crossley KO, Archer GL(eds), The Staphylococci in Human Diseases. New York: Churchill Livingston, 1997,55?81.
54. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med,2005,202(2):209?215.
55. Proctor RA, van Langevelde P, Kristjansson M, et al. Persistent and relapsing infections associated with smallcolony variants of Staphylococcus aureus. Clin Infect Dis,1995,20(1):95?102.
56. von Eiff C, Proctor RA, Peters G. Small colony variants of Staphylococci: a link to persistent infections. Berl Munch Tierarztl Wochenschr,2000,113(9):321?325.
57. Quie PG. Microcolonies (G-variants) of Staphylococcus aureus. Yale J Biol Med, 1969,41(5):394?403.
58. Wise RI, Spink WW. The influence of antibiotics on the origin of small colonies (G variants)of Micrococcus pyogenes var.aureus. J Clin Invest,1954, 33(12):1611?1622.
59. von Eiff C, Heilmann C, Proctor RA, et al. A sitedirected Staphylococcus aureus hemB mutant is a smallcolony variant which persists intracellularly. J Bacteriol, 1997,179(15):4706?4712.
60. Proctor RA, Kahl B, von Eiff C, et al. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis,1998,27 (Suppl 1):68?74.
61. Salgado DR, Bozza FA, Pinto M, et al. (2002) Outbreak with small colony variants of methicillin-resistant Staphylococcus aureus in an ICU. 41. Interscience Conference on Antimicrobial Agents and Chemotherapy. 16.?19.12. 2001, Chicago, Ill.
62. Balwit JM, van Langevelde P, Vann JM, et al. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J Infect Dis,1994,170(4):1033?1037.
63. Baumert N, von Eiff C, Schaaff F, et al. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist,2002, 8(4):253?260.
64. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis,1987,155(3):581?585.
65. Koo SP, Bayer AS, Sahl HG, et al. Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect Immun,1996,64(3):1070?1074.
66. Musher DM, Baughn RE, Templeton GB, et al. Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J Infect Dis,1977,136(3):360?369.
67. Spearman P, Lakey D, Jotte S, et al. Sternoclavicular joint septic arthritis with small-colony variant Staphylococcus aureus. Diagn Microbiol Infect Dis,1996 26(1):13?15.
68. Von Eiff C, Peters G, Becker K. The small colony variant (SCV) concept—the role of staphylococcal SCVs in persistent infections.Injury, Int. J. Care Injured ,2006, 37(2), S26—S33.
69. Harris LG, Richards RG. Staphylococci and implant surfaces: a review. Injury, Int. J. Care Injured (2006) 37, S3—S14.
70. Hussain M, Becker K, von Eiff C, et al. Identification and characterization of a novel
38.5-Kilodalton cell surface protein of Staphylococcus aureus with extended-spectrum binding activity for extracellular matrix and plasma proteins.J Bacteriol,2001, 183(23):6778?6786.
71. Brotz H, Sahl HG. New insights into the mechanism of action of antibiotics-diverse biological effects by binding to the same molecular target. J Antimicrob Chemother,2000,46(1):1?6.
72. Kocianova S, Vuong C, Yao Y, et al. Key role of polygamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest, 2005,115(3):688?694.
73. Berger-B?chi B, McCallum N. State of the knowledge of bacterial resistanceInjury, Int. J. Care Injured,2006,37(2),S20—S25.
74. Sieradzki K, Leski T, Dick J, et al. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo:multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for therapy. J Clin Microbiol, 2003,41(4):1687?1693.
75. Hooper DC. Fluoroquinolone resistance among Grampositive cocci. Lancet Infect.Dis,2002,2(9):530?538.
76. Chopra I, O’Neill AJ, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat,2003,6(3):137?145.
77. Prunier AL, Malbruny B, Laurans M, et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis,2003,187(11):1709?1716.
78. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis,2002, 34(4):482?492.
79. Perichon B, Courvalin P. Update on vancomycin resistance.Int J Pract,2000, 54(4):250?254.
80. Baptista M, Depardieu F, Reynolds P, et al. Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci. Mol Microbiol, 1997,25(1):93?105.
81. Martin JF, Casqueiro J, Liras P. Secretion systems for secondary metabolites: how porducer cells send out messages of intercellular communication. Curr Opin Microbiol,2005,8(3):282?293.
82. Osborn AM, B?ltner D. When phage, plasmids, and transposons collide: genomic islands, and conjugative-and mobilizable-transposons as a mosaic continuum. Plasmid,2002,48(3):202?212.
83. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother,1994,38(7):1147?1451.
84. Hakenbeck R. Transformation in Streptococcus pneumoniae: mosaic genes and the regulation of competence. Res Microbiol,2000,151(6):453?546.
85. Ochsner1 PE, Hailemariam S. Histology of osteosynthesis associated bone infection. Injury, Int Care Injured,2006,37(2),S49—S58.
86. Burri C. Posttraumatic osteitis. 2nd ed. Bern, Stuttgart, Wien: Huber-Verlag. 1979
87. Rittmann WW, Perren SM (1974) Cortical bone healing after osteosynthesis and infection. Berlin, Heidelberg, New York: Springer-Verlag.
88. Sevitt S. Bone repair and fracture healing in man. Edinburgh: Churchill Livingstone. 1981
89. B?hm E, H?rster HG. [Histological progress studies of osteomyelitis ltreated locallywith gentamycin]. Aktuelle Probl Chir Orthop, 1979,12:182?186.
90. Ochsner PE, Brunazzi MG. Intramedullary reaming and soft tissue procedures in treatment of chronic osteomyelitis of long bones. Orthopedics,1994,17(5):433?440.
91. Ochsner PE, Sokhegyi A, Petralli C. [The value of computerized tomography in the assessment of chronic osteomyelitis.A radiological, histological and clinical correlation study]. ZOrthop Ihre Grenzgeb,1990,128(3):313?318.
92. Ochsner PE, Baumgart F, Kohler G. Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal Injury,1998, 29 (Suppl)2: B1?B10.
93. Baumgart F, Kohler G, Ochsner PE. The physics of heat generation during reaming of the medullary cavity. Injury,1998,29(Suppl 2): B11?B25.
94. B?hm E. [Chronic posttraumatic osteomyelitis. Morphology and pathogenesis]. Unfallheilkunde,1986,176. 6-8.
95. Andrej Trampuz1, Werner Zimmerli. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury,2006,37(2),S59—S66.
96. Gustilo RB, Merkow RL, Templeman D. The management of open fractures. J Bone Joint Surg Am,1990,72(2):299?304.
97. Zych GA Hutson JJJ. Diagnosis and management of infection after tibial intramedullary nailing. Clin Orthop,1995,(315):153?162.
98. Murdoch DR, Roberts SA, Fowler JVJ, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis,2001,32(4):647?649.
99. Spangehl MJ, Masri BA, O’Connell JX, et al (1999) Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am, 81(5):672?683.
100. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis,2001,33Suppl 2:94?106.
101. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol,1999,37(10):3281?3290.
102. Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prostheticcomponents in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.J Clin Microbiol,2006,44(2):628?631.
103. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop,2003,414:69?88.
104. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.Radiology,2003,226(2):391-398.
105. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645-1654.
106. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249-256.
107. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA, 1998,279(19):1537-1541.
108. Giulieri SG, Graber P, Ochsner PE, et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection,2004, 32(4):222-228.
109. Widmer AF, Gaechter A, Ochsner PE, et al. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis, 1992,14(6): 1251-1253.
110. Pavoni GL, Falcone M, Baiocchi P, et al. Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience. J Chemother,2002,14(4):378-383.
111. Widmer AF, Frei R, Rajacic Z, et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis,1990, 162(1):96-102.
112. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc,2004,79(9):1137-1144.
113. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheralneuropathy associated with prolonged use of linezolid. Lancet Infect Dis,2004,4(8):528-531.
114. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy.Lancet,1996,347(9015):1579-1582.
115. Charnley J (1970) Acrylic cement in orthopedic surgery.Edinburgh and London: E&S Livingstone, 118-125.
116. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant- related infections by local application of antibiotics.Injury,2006,37, S95-S104.
117. Buchholz HW, Elson RA, Engelbrecht E, et al. Management of deep infection of total hip replacement. J Bone Joint Surg Br,1981,63-B(3):342-353.
118. Espehaug B, Engesaeter LB, Vollset SE et al. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg BR,1997, 79(4):590-595.
119. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
120. Tunney MM, Ramage G, Patrick S et al. Antimicrobial susceptibility of bacteria isolated from orthopedic implants following revision hip surgery. Antimicrob Agents Chemother,1998,42(11):3002-3005.
121. Kendall RW, Duncan CP, Smith JA et al. Persistence of bacteria on antibiotic loaded acrylic depots: A reason for caution. Clin Orthop,1996,329:273-280.
122. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
123. Klemm K (1979) [ Gentamicin PMMA-beads in treating bone and soft tissue infections (author’s transl)] Zentralbl Chir, 104(14):934-942.
124. Wahlig H, Dingeldein E, Bergmann R et al. The release of gentamicin from polymethlymethacrylate beads. An experimental and pharmacokinetic study. J Bone Joint Surg Br,1978,60-B(2):270-275.
125. Salvati EA, Callaghan JJ, Brause BD et al. Reimplantation in infection. Elution of gentamicin from cement and beads. Clin Orthop,1986,207:83-93.
126. Patzakis MJ, Mazur K, Wilkins J et al. Septopal beads and autogenous bone grafting for bone defects in patients with chronic osteomyelitis. Clin Orthop RelatRes,1993,295:112–118.
127. Calhoun JH, Henry SL, Anger DM et al. The treatment of infected nonunions with gentamicin-polymethylmethacrylate antibiotic beads. Clin Orthop Relat Res,1993, 295:23–27.
128. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
129. Riegels-Nielsen P, Espersen F, Holmich LR et al. Collagen with gentamicin for prophylaxis of postoperative infection. Staphylococcus aureus osteomyelitis studied in rabbits. Acta Orthop Scand,1995,66(1):69-72.
130. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
131. Ostermann PA, Henry SL, Seligson D. The role of local antibiotic therapy in the management of compound fractures. Clin Orthop Relat Res,1993,295:102-111.
132. Hettfleisch J, Schottle H (1993) [Local preventive antibiotic treatment in intramedullary nailing with gentamicin impregnated biomaterials] Aktuelle Traumatol, 23(2):68-71.
133. Eklund AM, Valtonen M, Werkkala KA. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery. J Hosp Infect,2005,59(2):108?112.
134. Friberg O, Svedjeholm R, Soderquist B et al. Local gentamicin reduces sternal wound infections after cardiac surgery: a randomised controlled trial. Ann Thorac Surg,2005, 79(1):153?162.
135. Ascherl R, Stemberger A, Lechner F et al. [Treatment of chronic osteomyelitis with a collagen-antibiotic compound–preliminary report.] Unfallchirurgie,1986, 12(3):125– 127.
136. Sorensen TS, Sorensen AI, Merser S. Rapid release of gentamicin from collagen sponge. In vitro comparison with plastic beads. Acta Orthop Scand,1990, 61(4): 353–356.
137. Mehta S, Humphrey JS, Schenkman DI et al. Gentamicin distribution from a collagencarrier. J Orthop Res,1996,14(5):749–754.
138. Walenkamp GHIM, Karsemaker S. Pharmacokinetics of two gentamicin collagen fleeces in animal experiments. Walenkamp GHIM (ed) Biomaterials in Surgery. Stuttgart,New York: Georg Thieme Verlag,1998,18–20.
139. Moser A. Comparative human pharmacokinetics of two gentamicin-containing collagen carriers. Walenkamp GHIM(ed) Biomaterials in Surgery. Stuttgart, New York: GeorgThieme Verlag,1998,21–24.
140. Humphrey JS, Mehta S, Seaber AV et al. Pharmacokinetics of a degradable drug delivery system in bone. Clin Orthop Relat Res,1998,349:218–224.
141. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
142. Mader JT, Calhoun J, Cobos J (1997) In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother,41(2):415–418.
143. Frommelt L.Principles of systemic antimicrobial therapy in foreign material associated infection in bone tissue,with special focus on periprosthetic infection. Injury,2006, 37(2),S87-S94.
144. Mader JT, Adams KR. Experimental osteomyelitis. Schlossberg D (ed) Orthopedic Infection. New York: Springer Verlag,1988,39?48.
145. Bengtson S, Knutson K. The infected knee arthroplasty.A 6-year follow-up of 357 cases. Acta Orthop Scand,1991,62(4):30111.
146. Tattevin P, Cremieux AC, Pottier P, et al. Prosthetic joint infection: When can prosthesis salvage be considered? Clin Infect Dis,1999,29(2):292?295.
147. Brause BD. Infection with prostheses in bone and joint. Mandell GL, Bennet JE, Dolin R (eds) Principles and practice of infectious Diseases. 5th ed. Philadelphia: Churchhill Livingstone,2000,1196?1200.
148. Goulet JA, Pellicci PM, Brause BD, et al. Prolonged suppression of infection in total hip arthroplasty. J Arthroplasty,1988,3(2):109?116.
149. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645?1654.
150. Mella-Schmidt C, Steinbrink K. [Value of irrigationsuction drainage in the treatmentof early infection of joint implants]. Chirurg,1989,60(11):791?794.
151. Robbins GM, Masri BA, Garbuz DS, et al. Primary Total hip arthroplasty after infection.J Bone Joint Surg Am,2001,83(4):601?614.
152. Frommelt L.[Guidelines on antimicrobial therapy in situations of periprosthetic THR infection]. Orthop?de,2004,33(7):822?826.
153. Langlais F, Lambotte JC, Thomazeau H. Treatment of infected hip replacement. Lemaire R, Herom F, Scott J, (eds),European Instructional Course Lectures Vol 6. London: The British Society of Bone and Joint Surgery,2003,158?167.
154. Haleem AA, Berry DJ, Hanssen AD. Mid-term to longterm followup of two-stage reimplantation for infected total knee arthroplasty. Clin Orthop Relat Res,2004, 428:35–39.
155. Henderson MH Jr, Booth RE Jr. The use of an antibioticimpregnated spacer block for revision of the septic total knee arthroplasty. Semin Arthroplasty,1991,2(1): 34–39.
156. Nazarian DG, de Jesus D, McGuigan F et al. A twostage approach to primary knee arthroplasty in the infected arthritic knee. J Arthroplasty,2003,18(7):16–21.
157. Wilde AH, Ruth JT. Two-stage reimplantation in infected total knee arthroplasty. Clin Orthop Relat Res,1988,236:23–35.
158. Calton TF, Fehring TK, Griffin WL. Bone loss associated with the use of spacer blocks in infected total knee arthroplasty. Clin Orthop Relat Res,1997, 345:148–154.
159. Hsieh PH, Shih CH, Chang YH et al. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J Bone Joint Surg Am,2004,86(9):1989?1997.
160. Schlegel U, Perren SM.Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection.Injury,2006,37(2), S67—S73
161. Melcher G, Claudi B, Schlegel U, et al. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. J Bone Joint Surg Br,1994,76(6):955?959.
162. Arens S, Eijer H, Schlegel U, et al. Influence of the design for fixation implants on local infection: Experimental study of dynamic compression plates versus point contact fixators in rabbits. J Orthop Trauma,1999,13(7):470?476.
163. Horn J, Schlegel U, Krettek C, et al. Infection resistance of unreamed solid, hollowslotted and cannulated intramedullary nails: an in-vivo experimental comparison. J Orthop Res,2005,23(4):810?815.
164. Hauke C, Schlegel U, Melcher GA, et al. Local infection in relation to different implant materials. An experimental study using stainless steel and titanium solid, unlocked, intramedullary nails in rabbits. Orthop Trans,1997,21:835?836.
165. Melcher GA, Metzdorf A, Schlegel U, et al. Influence of reaming versus nonreaming in intramedullary nailing on local infection rate: Experimental investigation in rabbits. J Trauma,1995,39(6):1123?1128.
166. Metzdorf A (1996) Einfluss der Markraumbohrung auf die Entstehung eines lokalen Infektes. Universit?t Würzburg. Dissertation.
167. Arens S, Schlegel U, Printzen G, et al. Influence of materials for fixation implants on local infection. An experimental study of steel versus titanium DCP in rabbits. J Bone Joint Surg Br,1996,78(4):647?651.
168. Eijer H, Arens S, Schlegel U, et al. Einfluss des Implantat-Designs auf die lokale Infektentstehung. Tierexperimentelle Untersuchung von DC-Platten und Point-Contact Fixateuren. Springer Verlag, Berlin. Hefte zu: Der Unfallchirurg, 1997,268, 855?856.
169. Mainil-Varlet P, Hauke C, Printzen G, et al. (1999) Polylactide implants for internal fixation of bacterially contaminated fractures. Stein H, Suk SE-II, Ping-Chung Leung (eds) SIROT 1999. Sydney: Freund Publishing House, 21?27.
170. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
171. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
172. Lucke M, Schmidmaier G, Sadoni S et al. Gentamicin coating of metal implants reduces implant-related osteomyelitis in rats. Bone,2003,32(5):521?531.
173. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2),S105-S112.
174. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000,282:362?363.
175. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59-S66.
176. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
177. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249?256.
178. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA,1998, 279(19):1537?1541.
179. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res,1999,(360):22?29.
180. Trampuz A, Gilomen A, Fluckiger U, et al. (2005) Treatment outcome of infections associated with internal fixation devices: Results from a 5-year retrospective study (1999-2003).45th ICAAC, American Society for Microbiology, December 16-19, 2005, Washington, DC; No. K-882.
181. Peter EO, Martin M, Christian P. Infection after osteosynthesis: a summary of the scientific presentations at the annual Swiss AO meeting 2005 in Liestal Injury,2006,37(2),S117-S119.
182. Lau YS, Wang W, Sabokbar A, et al.Staphylococcus aureus capsular material promotes osteoclast formation.Injury,2006,37(2),S41-S48.
183. Stallmann HP, Faber C, Amerongen AVN, et al.Antimicrobial peptides: review of their application in musculoskeletal infections Injury,2006,37(2),S34-S40.
184. Neut D, van de Belt H, Stokroos I, et al. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother,2001,47(6):885?891.
185. Helmerhorst EJ, Breeuwer P, van’t Hof W, et al. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem,1999, 274:7286?7291.
186. Helmerhorst EJ, Troxler RF, Oppenheim FG. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci USA, 2001,98:14637?14642.
187. Helmerhorst EJ, van’t Hof W, Breeuwer P, et al.Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation. J Biol Chem,2001,276(8):5643?5649.
188. Helmerhorst EJ, Murphy MP, Troxler RF, et al. Characterization of the mitochondrial respiratory pathways in Candida albicans. Biochim Biophys Acta,2002, 1556:73?80.
189. Zasloff M. Antimicrobial peptides of multicellular organisms.Nature,2002, 415(6870):389?395.
190. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis,2001,1(3):156?164.
191. Nibbering PH, Ravensbergen E, Welling MM, et al.Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun,2001,69(3):1469?1476.
192. Faber C, Hoogendoorn RJ, Stallmann HP, et al. In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemothe, 2004,54(6):1078?1084.
193. Faber C, Stallmann HP, Lyaruu DM, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother,2005, 49(6):2438?2444.
194. Stallmann HP, Faber C, Bronckers AL, et al. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother,2004,54(2):472?476.
195. Helmerhorst EJ, Hodgson R, van‘t Hof W, et al. The effects of histatin-derived basic antimicrobial peptides on oral biofilms. J Dent Res,1999,78(6):1245?1250.
196. Lupetti A, Paulusma-Annema A, Welling MM, et al.Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother,2000, 44(12):3257?3263.
197. Stallmann HP, Faber C, Bronckers AL, et al. Histatin and lactoferrin derived peptides: Antimicrobial properties and effects on mammalian cells. Peptides,2005, 26(12):2355?2359.
198. Hancock RE. Peptide antibiotics. Lancet,1997,349(9049):418?422.
199. Ganz T. Fatal attraction evaded. How pathogenic bacteria resist cationic polypeptides. J Exp Med,2001,193(9):F31?F34.
200. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev,2003,55(1):27?55.
201. Faber C, Stallmann HP, Lyaruu DM, et al. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J Antimicrob Chemother,2003,51(6):1359?1364.
202. Stallmann HP, Faber C, Slotema ET, et al. Continuousrelease or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes. J Antimicrob Chemother,2003,52(5):853?855.
203. Bartlett KH, McCray PB Jr, Thorne PS. Novispirin G10-induced lung toxicity in a Klebsiella pneumoniae infection model. Antimicrob Agents Chemother,2003, 47(12):3901?3906.
204. Lupetti A, Nibbering PH, Welling MM, et al. Radiopharmaceuticals: new antimicrobial agents. Trends Biotechnol,2003,21(2):70?73.
205. Lupetti A, Paulusma-Annema A, Welling MM, et al. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob Agents Chemother,2003,47(1):262?267.
206. Nekhotiaeva N, Elmquist A, Rajarao GK, et al. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J,2004,18(2):394?396.
1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med,2004,350(14):1422?1429.
2. Clifford RP. Open fractures. Rüedi TP, Murphy WM (eds), AO Principles of Fracture Management. AO Publishing, Stuttgart New York: Thieme-Verlag: 2000:621?643.
3. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma,2003,55(5):949?954.
4. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
5. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
6. Richards RG.Introduction: Implants and infection in fracture fixation“ten years on”.Injury,2006,37(2):S37-S38.
7. Ilyina TS , Romanova YH , Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body : the phenomenon , genetic control , and regulationsystems of development. Russian J Genetics,2004,40(11):1189-1198.
8. Cook DJ, Walter SD. Incidence of and risk factors for ventilator - associated pneumonia in crticallyill patients. Ann Intern Med,1998,129(6):433-401.
9. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics.Injury,2006,37(2), S95—S104.
10. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
11. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
12. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials,2003,24(10):1829–1831.
13. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin frombiodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
14. Beardmore AA, Brooks DE, Wenke JC et al. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am,2005,87(1):107-112.
15. Darouiche RO, Farmer J, Chaput C et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am,1998, 80(9):1336?1340.
16. Gollwitzer H, Ibrahim K, Meyer H et al. Antibacterialpoly (D,L-lactic acid) coating of medical implants using a biogradable drug delivery technology. J Antimicrob Chemother,2003,51(3):585?591.
17. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review.Injury, 2006,37(2): S105-S112.
18. Lucke M, Schmidmaier G, Wildemann B et al. Entwicklung einer biodegradierbaren und antibiotisch wirksamen Beschichtung von Implantaten. Hefte Z Unfall Chir,2000, 282:362?363.
1. European Antimicrobial Resistance Surveillance System Annual Report (EARSS) 2002.
2. Faisham WI, Nordin S, Aidura M. Bacteriological study and its role in the management of open tibial fracture. Med J Malaysia,2001,56(2):201?206.
3. Andrej Trampuz1, Werner Zimmerli. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury,2006,37(2),S59-S66.
4. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med, 2004,351(16):1645-1654.
5. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br,2005,87(2):249-256.
6. Giulieri SG, Graber P, Ochsner PE, et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection,2004, 32(4):222-228.
7. Pavoni GL, Falcone M, Baiocchi P, et al. Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience. J Chemother,2002,14(4):378-383.
8. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc,2004,79(9):1137-1144.
9. Diefenbeck M, Mückley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics.Injury,2006,37(2): S95—S104.
10. Liu SJ, Wen-Neng Ueng S, Lin SS et al. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res,2002,63(6):807–813.
11. Engesaeter LB, Lie SA, Espehaug B et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand,2003,74(6):644-651.
12. Hendriks JG, Neut D, van Horn JR et al. Bacterial survival in the interfacial gap in gentamicin-loaded acrylic bone cements. J Bone Joint Surg Br,2005, 87(2):272-276.
13. Schlegel U, Perren SM. Surgical aspects of infection involving osteosynthesis implants: implant design and resistance to local infection.Injury,2006,37,S67-S73.
14. Schmidmaier G, Lucke M, Wildemann1 B,et al. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury, 2006,37(2), S105-S112.
15. Trampuz1 A, Zimmerli W.Diagnosis and treatment of infections associated with fracture-fixation devicesInjury,2006,37(2),S59-S66.
16. Neut D, van de Belt H, Stokroos I, et al. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother,2001,47(6):885?891.
17. Stallmann HP, Faber C, Amerongen AVN, et al.Antimicrobial peptides: review of their application in musculoskeletal infections. Injury,2006,37(2),S34-S40.
18. Stallmann HP, Faber C, Bronckers AL, et al. Histatin and lactoferrin derived peptides: Antimicrobial properties and effects on mammalian cells. Peptides,2005,26(12): 2355?2359.
19. Faber C, Hoogendoorn RJ, Stallmann HP, et al. In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemother, 2004,54(6):1078?1084.
20. Faber C, Stallmann HP, Lyaruu DM, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother,2005, 49(6):2438?2444.